蜈蚣提取液治疗乳腺癌的实验研究
|
摘要
第一章蜈蚣提取液对三阴性乳腺癌MDA-MB-231细胞体外抗癌作用及机制的研究
目的：研究蜈蚣提取液对乳腺癌细胞株的敏感性、作用的细胞周期时相及作用机制,为乳腺癌的临床治疗提供理论依据。
方法：体外培养三阴性乳腺癌细胞MDA-MB-231,采用不同浓度蜈蚣提取液(Extract of Centipede, ECP)予以干预,通过MTT实验、细胞的药物浓度一时间生长曲线研究其对乳腺癌细胞株的敏感性；利用倒置光学显微镜和电子显微镜观察细胞形态及其超微结构的变化；流式细胞仪检测药物治疗组的细胞周期及其凋亡率；免疫组织化学法检测细胞内凋亡相关基因Bcl-2及Bax的表达情况。结果：①MTT法揭示各浓度ECP对人乳腺癌细胞MDA-MB-231生长均有抑制作用。ECP在80mg/ml、40mg/ml.20mg/ml.10mg/ml.5mg/ml、2.5mg/ml及1.25mg/ml下对MDA-MB-231的抑制率依次为(71.26±2.64)％、(62.48±6.67)％.(56.26±3.17)％.(48.63±4.48)％.(42.13±4.73)％、(34.5±2.98)％和(26.89±2.95)％,中效浓度为12.5mg/ml.②细胞生长曲线图显示MDA-MB-231活细胞数目与ECP浓度及药物作用时间相关。治疗组浓度在12.5mg/ml与25mg/ml时,用药后24小时活细胞数就显著减少。各组间活细胞数比较差异明显(P<0.01)。③光镜下见ECP作用48小时后,浓度低于10mg/ml对MDA-MB-231细胞无明显的抑制作用,浓度在10mg/ml以上时,MDA-MB-231活细胞数减少,细胞形态变圆变小,80mg/ml时见细胞大片坏死,有较多的不规则细胞碎片,培养瓶中坏死脱落细胞增多。电镜下见治疗组细胞密度增高,染色质凝集固缩,染色质边集,核固缩、核碎裂,及凋亡小体的形成。④流式细胞仪检测发现：(A)ECP在不同浓度下,G0/G1期所占的比例是不同的。对照组为(36.7+4.2)%,浓度12.5mg/ml为(56.5±4.1)％,25mg/ml组最高,为(67.3±4.4)%。(B)细胞增殖指数(PI)：在对照组为(63.3±3.2)%,浓度12.5mg/ml时为(43.5±3.5)％,25mg/ml时为(32.7±2.0)%,差异显著(P<0.05)。并且,随着药物浓度的增高,细胞凋亡所出现的“亚G1峰”是逐步增高的。(C)细胞凋亡率：培养及作用48小时后对照组的自发凋亡率(2.15±0.13)%,浓度12.5mg/ml时为(13.01±1.51)％,25mg/ml时为(21.3±1.98)%,各浓度组间差异明显(P<0.05)。⑤免疫组化法检测MDA-MB-231细胞的Bcl-2和Bax表达,对照组中Bcl-2的OD值最大,染色最深、最多,随ECP浓度加大,Bcl-2在MDA-MB-231细胞的OD值逐渐变小,染色逐步变少、变浅。在对照组中,Bax的OD值最小,染色浅而少,随ECP浓度加大,表达Bax的细胞的OD值依次变大,染色逐步变多,颜色加深。
结论：①ECP能抑制人三阴性乳腺癌细胞MDA-MB-231的增殖,且抑制作用呈剂量和时间依赖效应；②ECP低浓度有诱导肿瘤细胞凋亡作用,中、高浓度有直接杀伤肿瘤细胞作用。③ECP作用MDA-MB-231细胞的G1/GO期,抑制其增殖,并能诱导其凋亡,其作用呈剂量和时间依赖效应；④ECP治疗三阴性乳腺癌MDA-MB-231细胞后能促进Bax基因的表达,抑制Bcl-2基因的表达。。
第二章.蜈蚣提取液体内抑癌及作用机制的研究
目的：研究蜈蚣提取液在体内对乳腺癌是否有抑制作用,并探讨蜈蚣提取液抑制乳腺癌细胞生长的机制。
方法：建立裸鼠MDA-MB-231人异位乳腺癌移植模型,以蜈蚣提取液予以灌服,观察肿瘤生长、乳腺癌转移情况。②运用免疫组化法对肿瘤组织标本进行Bcl-2、Bax、血管内皮细胞生长因子(Vascular Endothelial Growth Factor, VEGF)和促血管生成素2(Angiopoietin2,Ang-2)的检测。
结果：①裸鼠MDA-MB-231人异位乳腺癌移植模型成功率100%②蜈蚣提取液对裸鼠MDA-MB-231移植瘤有明显抑制作用,在移植后第25天,对照组的肿瘤平均体积为(1011.52±212.68)mm3,治疗组为(238.83±65.45)mm3；裸鼠处死后,对照组的肿瘤平均重量为(983+97.3)mg,治疗组为(556+98.1)mg,抑制率达44.2%,两组有显著差异性。③在对照组中,Bcl-2、VEGF与Ang-2的染色细胞数、染色强度及OD值均较治疗组多而强,而Bax的染色强度、染色细胞数及OD值较治疗组要少而弱,它们比较均有显著性差异(p<0.01)。
结论：蜈蚣提取液能抑制裸鼠MDA-MB-231移植瘤的生长,其机理与抑制肿瘤血管生成、促进肿瘤细胞凋亡有关。
第三章蛋白质组学技术和方法分离治疗组乳腺癌细胞的差异表达蛋白
目的：筛选蜈蚣提取液治疗乳腺癌细胞后的相关差异蛋白,探讨药物治疗乳腺癌的机理。
方法：运用蛋白质组学技术和方法,采用一步抽提法制备乳腺癌MDA-MB-231细胞株治疗组和对照组的总蛋白质,用双向凝胶电泳技术建立了重复性和分辨率均较好的MDA-MB-231细胞株治疗组和对照组总蛋白的双向凝胶电泳图谱。PDQuest软件对两组细胞蛋白质的双向电泳图谱进行了比较,并采用MALDI-TOF-MS对差异表达的蛋白质进行分析,获取MALDI-TOF-MS肽质量指纹图谱,数据库搜索鉴定主要差异表达的蛋白质。
结果：①共发现76个差异表达蛋白点(p<0.05)。治疗组中41个表达下调,35个表达上调。②选择其中明显的12个蛋白质斑点作为差异表达的质谱分析,分析出11个差异蛋白。5个蛋白质即：S100A9、CALML5、CK-19、Gal-7和α-烯醇化酶在MDA-MB-231治疗组中表达上调；而6个蛋白质即GST01-1、PGAMA、HSP90-β、AKP-P. IMPDH和GAPDH在MDA-MB-231治疗组中表达下调。
结论：①对双向凝胶电泳图谱分析共发现76个差异表达蛋白,41个表达下调,35个表达上调。②质谱分析11个差异蛋白,S100A9、 CALML5、CK-19、Gal-7和α-烯醇化酶在MDA-MB-231治疗组中表达上调；而6个蛋白质即GST01-1、PGAMA、HSP90-β、AKP-P、IMPDH和GAPDH在MDA-MB-231治疗组中表达下调。提示蜈蚣提取液能多途径抑制乳腺癌细胞的生长,诱导乳腺癌细胞凋亡或直接死亡。
第四章部分蛋白质分子差异表达水平验证研究
目的：验证比较蛋白质组学研究结果。
方法：采用Western-blot技术对S100A9蛋白、细胞角蛋白19、半乳凝素-7在MDA-MB-231细胞株治疗组与对照组中的表达水平进行了检测验证。
结果：S100A9蛋白、细胞角蛋白19、半乳凝素-7在MDA-MB-231治疗组中表达上调,与蛋白质组学研究结果一致。
结论：蛋白质组学方法筛选到的差异表达蛋白确实在MDA-MB-231细胞株治疗组和对照组存在差异表达。
Chapter Ⅰ Assay sensibility of brest cancer MDA-MB-231Cell line to ECP in vitro
Objective:To investigate sensitivity,targeted cell cycle phase and possible mechanism of the effect of centipede extract on breast cancer cell lines and provide evidences for further clinic therapy of breast cancer.
Methods:Cultured breast cancer cells MDA-MB-231are intervened with different concentration of centipede extract. MTT assay and concentration-time curve are used to study the effect sensitivity of centipede extract on breast cancer cell lines; Inverted light microscope and electron microscope are used to observe cell changes in morphology and ultrastructure; flow cytometry is applicated to investigate cell cycle and apoptosis rate in centipede extract-treated group.
Results:①The results of MTT assay showed that different concentrations of centipede extract all can inhibit the growth of human breast cancer cells MDA-MB-231.The inhibition rates were (71.26±2.64)%,(62.48±6.67)%,(56.26±3.17)%,(48.63±4.48)%,(42.13± 4.73)%,(34.5±2.98)%and (26.89±2.95)%respectively,while the Corresponding concentration of centipede extract were80mg/ml,40mg/ml,20mg/ml,10mg/ml,5mg/ml,2.5mg/ml and1.25mg/ml. IC50of centipede extract to MDA-MB-231was12.5mg/ml.②Drug concentration-time curve revealed that the viable cell counts of MDA-MB-231has direct relations with the concentration and administrative time of centipede extract. When treated with12.5mg/ml and25mg/ml centipede extract, viable counts of MDA-MB-231sharply decrease after24hours treatment and the difference among treatment groups is significant (P<0.01).③After48hr intervention, there were no inhibitory effect observed by light microscopy in groups with concentration less than10mg/ml; viable counts of MDA-MB-231decreased and the cells transformed to round and small when concentration were more than10mg/ml; With treated with80mg/ml, large number of necrotic cells and irregular cell debris were seemed. Meanwhile, margination and condensation of chromatin, fragmentation and condensation of nucleus and formation of apoptotic bodies were found in cells by electron microscope which had higher density④The result of flow cytometry displayed that (A)The ratio of G0/G1phase was varied by different concentrations of centipede extract:(36.7±4.2)%in control group,(56.5±4.1)%in12.5mg/ml group, and (67.3±4.4)%which was the highest in25mg/ml group.(B) Cell proliferation index (PI) of MDA-MB-231cells was significantly different as well (P<0.05):the values in control group,12.5mg/ml group and25mg/ml group were (63.3±3.2)%,(43.5±3.5)%, and(32.7±2.0)%,respectively. With the increased concentration of centipede extract, the "sub-G1peak" corresponding to apoptotic cells was gradually rising.(C) Apoptosis ratio: After48hr intervention, spontaneous apoptosis ratio in control group was (2.15±0.13)%, while in12.5mg/ml group it was (13.01±1.51)%and (21.3±1.98)%in25mg/ml group. The differences were statistically significant (P<0.05);⑤Immunohistochemistry had detected that the expression of Bcl-2gene was gradually weaken but that of Bax enhanced in MDA-MB-231cells with the increased concentration of centipede extract.
Conclusion:①Extract of centipede can inhibit the growing of human breast cancer cells MDA-MB-231and the effect was concentration-time dependent;②Extract of centipede can induce MDA-MB-231cell line to apoptosis in low concentration and directly kill it in middle or high concentration;③Extract of centipede to MDA-MB-231cells were held in G1/G0phase,inhibition of its growing,and can induce apoptosis in concentration-time depedent effects.④One of the possible mechanisms of Centipede extract treatment may be owned to its ability of promoting the expression of Bax gene and inhibiting that of Bcl-2gene in MDA-MB-231.
Chapter II Investigation to the effect and mechanisms of breast cancer MDA-MB-231treatment with ECP in vivo
Objective:To investigate the effects and mechanisms of breast cancer MDA-MB-231treatment with ECP.
Method:①To set up model of heterotopic grafting carcinoma for breast cancer for MDA-MB-231in nude mouse, and observe its tumor growth and metastasis by intragastric administration of ECP.②To detect Bcl-2、Bax、VEGF and Ang-2in tumor tissue with immunohistochemical methods
Result:①The achievement ratio for hefterotopic grafting carcinoma for breast cancer MDA-MB-231in nude mouse is100%.②It has distinctive inhibitive effect for ECP to hefterotopic grafting carcinoma for breast cancer MDA-MB-231in nude mouse. At the25th day postgraft of nude mouse,the average grafting carcinoma volume of the contrast is (1011.52±212.68)mm3, but for the treatment group is (238.83±65.45) mm3;The average grafting carcinoma weight of the contrast is (983±97.3)mg, but for the treatment group is (556±98.1)mg, The inhibitive ratio reaches to44.2%. there are significant difference for them (P<0.05).③The staining cells population, staining intensity and the optical density (OD) of Bcl-2,VEGF and Ang-2for the contrast group are higher than the treatment group, but they are lower for Bax. there are significant difference for them (P＜0.01)
Conclusion:ECP can inhibit hefterotopic grafting carcinoma for breast cancer MDA-MB-231in nude mouse, the mechanisms relate to inhibit tumor Angiogenesis and to promote cells to apoptosis..
Chapter Ⅲ:Application of the techniques and methods of Proteomics into separating differential expression proteins in breast cancer cells treatment with ECP
Objective:To screen the relevant differential expression proteins after treatment with ECP, and to investigate the molecule mechanism of ECP for breast cancer MDA-MB-231.
Method:we use proteomic Techniques and methods to analysis the mechanism of treatment with ECP for breast cancer MDA-MB-231. Firstly, comparative two-dimensional gel electrophoresis (2-DE) technology was applied to separate the total protein of MDA-MB-231 treatment group by ECP and its control group respectively. The well-resolved, reproducible2-DE patterns of treatment group of ECP and control group were established. Then, PDQuest software was used to analyze2-DE images, and the differential expression proteins between the two groups were identified by both peptide mass fingerprint (PMF) and peptide sequence tag (PST) based on MALDI-TOF-MS (Matrix-assisted laser desorption/ionization time of flight mass spectrometry).
Result:We select the differential expression proteins for between treatment group and control group which spots variance is over double to analyse with MALDI-TOF-MS after spots enzymolyed,and found out76protein spots at difference level of expression (p<0.05), including41spots decreasing in treatment group, and35spots increasing in control groups.12of the total pieces of PMF were be matched searching in SWISS-PROT/TREMBL database by Mascot software. Among the identified12protein spots, the expression level of proteins which up-regulates in treatment group is5in total including:S100A9、 CALML5、CK-19、Gal-7、Alpha-enolase. But6proteins in treatment group is down-regulation, which include GSTO1-1、PGAMA、HSP90-β、 AKP-P、IMPDH and GAPDH.
Conclusion:①Through analysis of two-dimensional gel electrophoresis (2-DE),76protein spots at difference level of expression (p<0.05) have been found out, including41spots decreasing in treatment group, and35spots increasing in control groups.②Among the identified11of the total of protein spots, the expression level of proteins which up-regulates in treatment group is5in total including:S100A9、 CALML5、CK-19、Gal-7、Alpha-enolase and which down-regulates in treatment group is6proteins in total, including:GSTO1-1、PGAMA、 HSP90-β、AKP-P、IMPDH and GAPDH.. It hint that ECP can inhibit MDA-MB-231cell line to growth by inducing it to apoptosis or directly to death in multi-channels.
Chapter Ⅳ:Verification of the differential expression levels of the partial proteins by western-blotting analysis and its function study
Objective:To verify the differential expression levels of the partial proteins S100A9、CK19and Gal-7which identified with compared proteomic techniques.
Method:To verify the differential expression levels of S100A9、 CK19and Gal-7again by Western-blot methods, which express in MDA-MB-231treatment with ECP group and control group ever identified with comparative proteomic techniques.
Result:The proteins of S100A9、CK19and Gal-7express up-regulation in treatment group with ECP, and the results were identical with the proteome analysis.
Conclusion:The differential expression proteins of S100A9、CK19and Gal-7screened by proteome analysis are indeed differential expression in treatment group and control group of MDA-MB-231cell.
目的：研究蜈蚣提取液对乳腺癌细胞株的敏感性、作用的细胞周期时相及作用机制,为乳腺癌的临床治疗提供理论依据。
方法：体外培养三阴性乳腺癌细胞MDA-MB-231,采用不同浓度蜈蚣提取液(Extract of Centipede, ECP)予以干预,通过MTT实验、细胞的药物浓度一时间生长曲线研究其对乳腺癌细胞株的敏感性；利用倒置光学显微镜和电子显微镜观察细胞形态及其超微结构的变化；流式细胞仪检测药物治疗组的细胞周期及其凋亡率；免疫组织化学法检测细胞内凋亡相关基因Bcl-2及Bax的表达情况。结果：①MTT法揭示各浓度ECP对人乳腺癌细胞MDA-MB-231生长均有抑制作用。ECP在80mg/ml、40mg/ml.20mg/ml.10mg/ml.5mg/ml、2.5mg/ml及1.25mg/ml下对MDA-MB-231的抑制率依次为(71.26±2.64)％、(62.48±6.67)％.(56.26±3.17)％.(48.63±4.48)％.(42.13±4.73)％、(34.5±2.98)％和(26.89±2.95)％,中效浓度为12.5mg/ml.②细胞生长曲线图显示MDA-MB-231活细胞数目与ECP浓度及药物作用时间相关。治疗组浓度在12.5mg/ml与25mg/ml时,用药后24小时活细胞数就显著减少。各组间活细胞数比较差异明显(P<0.01)。③光镜下见ECP作用48小时后,浓度低于10mg/ml对MDA-MB-231细胞无明显的抑制作用,浓度在10mg/ml以上时,MDA-MB-231活细胞数减少,细胞形态变圆变小,80mg/ml时见细胞大片坏死,有较多的不规则细胞碎片,培养瓶中坏死脱落细胞增多。电镜下见治疗组细胞密度增高,染色质凝集固缩,染色质边集,核固缩、核碎裂,及凋亡小体的形成。④流式细胞仪检测发现：(A)ECP在不同浓度下,G0/G1期所占的比例是不同的。对照组为(36.7+4.2)%,浓度12.5mg/ml为(56.5±4.1)％,25mg/ml组最高,为(67.3±4.4)%。(B)细胞增殖指数(PI)：在对照组为(63.3±3.2)%,浓度12.5mg/ml时为(43.5±3.5)％,25mg/ml时为(32.7±2.0)%,差异显著(P<0.05)。并且,随着药物浓度的增高,细胞凋亡所出现的“亚G1峰”是逐步增高的。(C)细胞凋亡率：培养及作用48小时后对照组的自发凋亡率(2.15±0.13)%,浓度12.5mg/ml时为(13.01±1.51)％,25mg/ml时为(21.3±1.98)%,各浓度组间差异明显(P<0.05)。⑤免疫组化法检测MDA-MB-231细胞的Bcl-2和Bax表达,对照组中Bcl-2的OD值最大,染色最深、最多,随ECP浓度加大,Bcl-2在MDA-MB-231细胞的OD值逐渐变小,染色逐步变少、变浅。在对照组中,Bax的OD值最小,染色浅而少,随ECP浓度加大,表达Bax的细胞的OD值依次变大,染色逐步变多,颜色加深。
结论：①ECP能抑制人三阴性乳腺癌细胞MDA-MB-231的增殖,且抑制作用呈剂量和时间依赖效应；②ECP低浓度有诱导肿瘤细胞凋亡作用,中、高浓度有直接杀伤肿瘤细胞作用。③ECP作用MDA-MB-231细胞的G1/GO期,抑制其增殖,并能诱导其凋亡,其作用呈剂量和时间依赖效应；④ECP治疗三阴性乳腺癌MDA-MB-231细胞后能促进Bax基因的表达,抑制Bcl-2基因的表达。。
第二章.蜈蚣提取液体内抑癌及作用机制的研究
目的：研究蜈蚣提取液在体内对乳腺癌是否有抑制作用,并探讨蜈蚣提取液抑制乳腺癌细胞生长的机制。
方法：建立裸鼠MDA-MB-231人异位乳腺癌移植模型,以蜈蚣提取液予以灌服,观察肿瘤生长、乳腺癌转移情况。②运用免疫组化法对肿瘤组织标本进行Bcl-2、Bax、血管内皮细胞生长因子(Vascular Endothelial Growth Factor, VEGF)和促血管生成素2(Angiopoietin2,Ang-2)的检测。
结果：①裸鼠MDA-MB-231人异位乳腺癌移植模型成功率100%②蜈蚣提取液对裸鼠MDA-MB-231移植瘤有明显抑制作用,在移植后第25天,对照组的肿瘤平均体积为(1011.52±212.68)mm3,治疗组为(238.83±65.45)mm3；裸鼠处死后,对照组的肿瘤平均重量为(983+97.3)mg,治疗组为(556+98.1)mg,抑制率达44.2%,两组有显著差异性。③在对照组中,Bcl-2、VEGF与Ang-2的染色细胞数、染色强度及OD值均较治疗组多而强,而Bax的染色强度、染色细胞数及OD值较治疗组要少而弱,它们比较均有显著性差异(p<0.01)。
结论：蜈蚣提取液能抑制裸鼠MDA-MB-231移植瘤的生长,其机理与抑制肿瘤血管生成、促进肿瘤细胞凋亡有关。
第三章蛋白质组学技术和方法分离治疗组乳腺癌细胞的差异表达蛋白
目的：筛选蜈蚣提取液治疗乳腺癌细胞后的相关差异蛋白,探讨药物治疗乳腺癌的机理。
方法：运用蛋白质组学技术和方法,采用一步抽提法制备乳腺癌MDA-MB-231细胞株治疗组和对照组的总蛋白质,用双向凝胶电泳技术建立了重复性和分辨率均较好的MDA-MB-231细胞株治疗组和对照组总蛋白的双向凝胶电泳图谱。PDQuest软件对两组细胞蛋白质的双向电泳图谱进行了比较,并采用MALDI-TOF-MS对差异表达的蛋白质进行分析,获取MALDI-TOF-MS肽质量指纹图谱,数据库搜索鉴定主要差异表达的蛋白质。
结果：①共发现76个差异表达蛋白点(p<0.05)。治疗组中41个表达下调,35个表达上调。②选择其中明显的12个蛋白质斑点作为差异表达的质谱分析,分析出11个差异蛋白。5个蛋白质即：S100A9、CALML5、CK-19、Gal-7和α-烯醇化酶在MDA-MB-231治疗组中表达上调；而6个蛋白质即GST01-1、PGAMA、HSP90-β、AKP-P. IMPDH和GAPDH在MDA-MB-231治疗组中表达下调。
结论：①对双向凝胶电泳图谱分析共发现76个差异表达蛋白,41个表达下调,35个表达上调。②质谱分析11个差异蛋白,S100A9、 CALML5、CK-19、Gal-7和α-烯醇化酶在MDA-MB-231治疗组中表达上调；而6个蛋白质即GST01-1、PGAMA、HSP90-β、AKP-P、IMPDH和GAPDH在MDA-MB-231治疗组中表达下调。提示蜈蚣提取液能多途径抑制乳腺癌细胞的生长,诱导乳腺癌细胞凋亡或直接死亡。
第四章部分蛋白质分子差异表达水平验证研究
目的：验证比较蛋白质组学研究结果。
方法：采用Western-blot技术对S100A9蛋白、细胞角蛋白19、半乳凝素-7在MDA-MB-231细胞株治疗组与对照组中的表达水平进行了检测验证。
结果：S100A9蛋白、细胞角蛋白19、半乳凝素-7在MDA-MB-231治疗组中表达上调,与蛋白质组学研究结果一致。
结论：蛋白质组学方法筛选到的差异表达蛋白确实在MDA-MB-231细胞株治疗组和对照组存在差异表达。
Chapter Ⅰ Assay sensibility of brest cancer MDA-MB-231Cell line to ECP in vitro
Objective:To investigate sensitivity,targeted cell cycle phase and possible mechanism of the effect of centipede extract on breast cancer cell lines and provide evidences for further clinic therapy of breast cancer.
Methods:Cultured breast cancer cells MDA-MB-231are intervened with different concentration of centipede extract. MTT assay and concentration-time curve are used to study the effect sensitivity of centipede extract on breast cancer cell lines; Inverted light microscope and electron microscope are used to observe cell changes in morphology and ultrastructure; flow cytometry is applicated to investigate cell cycle and apoptosis rate in centipede extract-treated group.
Results:①The results of MTT assay showed that different concentrations of centipede extract all can inhibit the growth of human breast cancer cells MDA-MB-231.The inhibition rates were (71.26±2.64)%,(62.48±6.67)%,(56.26±3.17)%,(48.63±4.48)%,(42.13± 4.73)%,(34.5±2.98)%and (26.89±2.95)%respectively,while the Corresponding concentration of centipede extract were80mg/ml,40mg/ml,20mg/ml,10mg/ml,5mg/ml,2.5mg/ml and1.25mg/ml. IC50of centipede extract to MDA-MB-231was12.5mg/ml.②Drug concentration-time curve revealed that the viable cell counts of MDA-MB-231has direct relations with the concentration and administrative time of centipede extract. When treated with12.5mg/ml and25mg/ml centipede extract, viable counts of MDA-MB-231sharply decrease after24hours treatment and the difference among treatment groups is significant (P<0.01).③After48hr intervention, there were no inhibitory effect observed by light microscopy in groups with concentration less than10mg/ml; viable counts of MDA-MB-231decreased and the cells transformed to round and small when concentration were more than10mg/ml; With treated with80mg/ml, large number of necrotic cells and irregular cell debris were seemed. Meanwhile, margination and condensation of chromatin, fragmentation and condensation of nucleus and formation of apoptotic bodies were found in cells by electron microscope which had higher density④The result of flow cytometry displayed that (A)The ratio of G0/G1phase was varied by different concentrations of centipede extract:(36.7±4.2)%in control group,(56.5±4.1)%in12.5mg/ml group, and (67.3±4.4)%which was the highest in25mg/ml group.(B) Cell proliferation index (PI) of MDA-MB-231cells was significantly different as well (P<0.05):the values in control group,12.5mg/ml group and25mg/ml group were (63.3±3.2)%,(43.5±3.5)%, and(32.7±2.0)%,respectively. With the increased concentration of centipede extract, the "sub-G1peak" corresponding to apoptotic cells was gradually rising.(C) Apoptosis ratio: After48hr intervention, spontaneous apoptosis ratio in control group was (2.15±0.13)%, while in12.5mg/ml group it was (13.01±1.51)%and (21.3±1.98)%in25mg/ml group. The differences were statistically significant (P<0.05);⑤Immunohistochemistry had detected that the expression of Bcl-2gene was gradually weaken but that of Bax enhanced in MDA-MB-231cells with the increased concentration of centipede extract.
Conclusion:①Extract of centipede can inhibit the growing of human breast cancer cells MDA-MB-231and the effect was concentration-time dependent;②Extract of centipede can induce MDA-MB-231cell line to apoptosis in low concentration and directly kill it in middle or high concentration;③Extract of centipede to MDA-MB-231cells were held in G1/G0phase,inhibition of its growing,and can induce apoptosis in concentration-time depedent effects.④One of the possible mechanisms of Centipede extract treatment may be owned to its ability of promoting the expression of Bax gene and inhibiting that of Bcl-2gene in MDA-MB-231.
Chapter II Investigation to the effect and mechanisms of breast cancer MDA-MB-231treatment with ECP in vivo
Objective:To investigate the effects and mechanisms of breast cancer MDA-MB-231treatment with ECP.
Method:①To set up model of heterotopic grafting carcinoma for breast cancer for MDA-MB-231in nude mouse, and observe its tumor growth and metastasis by intragastric administration of ECP.②To detect Bcl-2、Bax、VEGF and Ang-2in tumor tissue with immunohistochemical methods
Result:①The achievement ratio for hefterotopic grafting carcinoma for breast cancer MDA-MB-231in nude mouse is100%.②It has distinctive inhibitive effect for ECP to hefterotopic grafting carcinoma for breast cancer MDA-MB-231in nude mouse. At the25th day postgraft of nude mouse,the average grafting carcinoma volume of the contrast is (1011.52±212.68)mm3, but for the treatment group is (238.83±65.45) mm3;The average grafting carcinoma weight of the contrast is (983±97.3)mg, but for the treatment group is (556±98.1)mg, The inhibitive ratio reaches to44.2%. there are significant difference for them (P<0.05).③The staining cells population, staining intensity and the optical density (OD) of Bcl-2,VEGF and Ang-2for the contrast group are higher than the treatment group, but they are lower for Bax. there are significant difference for them (P＜0.01)
Conclusion:ECP can inhibit hefterotopic grafting carcinoma for breast cancer MDA-MB-231in nude mouse, the mechanisms relate to inhibit tumor Angiogenesis and to promote cells to apoptosis..
Chapter Ⅲ:Application of the techniques and methods of Proteomics into separating differential expression proteins in breast cancer cells treatment with ECP
Objective:To screen the relevant differential expression proteins after treatment with ECP, and to investigate the molecule mechanism of ECP for breast cancer MDA-MB-231.
Method:we use proteomic Techniques and methods to analysis the mechanism of treatment with ECP for breast cancer MDA-MB-231. Firstly, comparative two-dimensional gel electrophoresis (2-DE) technology was applied to separate the total protein of MDA-MB-231 treatment group by ECP and its control group respectively. The well-resolved, reproducible2-DE patterns of treatment group of ECP and control group were established. Then, PDQuest software was used to analyze2-DE images, and the differential expression proteins between the two groups were identified by both peptide mass fingerprint (PMF) and peptide sequence tag (PST) based on MALDI-TOF-MS (Matrix-assisted laser desorption/ionization time of flight mass spectrometry).
Result:We select the differential expression proteins for between treatment group and control group which spots variance is over double to analyse with MALDI-TOF-MS after spots enzymolyed,and found out76protein spots at difference level of expression (p<0.05), including41spots decreasing in treatment group, and35spots increasing in control groups.12of the total pieces of PMF were be matched searching in SWISS-PROT/TREMBL database by Mascot software. Among the identified12protein spots, the expression level of proteins which up-regulates in treatment group is5in total including:S100A9、 CALML5、CK-19、Gal-7、Alpha-enolase. But6proteins in treatment group is down-regulation, which include GSTO1-1、PGAMA、HSP90-β、 AKP-P、IMPDH and GAPDH.
Conclusion:①Through analysis of two-dimensional gel electrophoresis (2-DE),76protein spots at difference level of expression (p<0.05) have been found out, including41spots decreasing in treatment group, and35spots increasing in control groups.②Among the identified11of the total of protein spots, the expression level of proteins which up-regulates in treatment group is5in total including:S100A9、 CALML5、CK-19、Gal-7、Alpha-enolase and which down-regulates in treatment group is6proteins in total, including:GSTO1-1、PGAMA、 HSP90-β、AKP-P、IMPDH and GAPDH.. It hint that ECP can inhibit MDA-MB-231cell line to growth by inducing it to apoptosis or directly to death in multi-channels.
Chapter Ⅳ:Verification of the differential expression levels of the partial proteins by western-blotting analysis and its function study
Objective:To verify the differential expression levels of the partial proteins S100A9、CK19and Gal-7which identified with compared proteomic techniques.
Method:To verify the differential expression levels of S100A9、 CK19and Gal-7again by Western-blot methods, which express in MDA-MB-231treatment with ECP group and control group ever identified with comparative proteomic techniques.
Result:The proteins of S100A9、CK19and Gal-7express up-regulation in treatment group with ECP, and the results were identical with the proteome analysis.
Conclusion:The differential expression proteins of S100A9、CK19and Gal-7screened by proteome analysis are indeed differential expression in treatment group and control group of MDA-MB-231cell.
引文
[1]Law RenceW,Norton,李芬芳等.美国乳腺癌治疗现状[J].陕西肿瘤医学,2000,8(2)：123.
[2]Chow LWC,LooWTY. The differential effects of cyclophosphamide, epirubicinand-fluorouracil on apoptotic marker (CPP-32), pro-ap-optotic protein (p21waf-1) and anti-apoptotic protein (bcl-2) in breast cancer cells[J].Breast Cancer Res Treat,2003,80 (3):239-244.
[3]陈孝平,石应康,邱贵兴,主编.外科学[M].北京：人民卫生出版社,2005,439.
[4]常卫华,王留兴等.乳腺癌分子靶向治疗的进展与展望[J].肿瘤基础与临床,2009,22(3)：270-271.
[5]Jacobs JR,Bovasso GB.Early and chronic stress and their relation to breast cancer[J].PsycholMed,2004,30(3):669-678.
[6]朱珍,张凤春.晚期乳腺癌的化疗进展[J].现代肿瘤医学,2009,17(6)：1179-1181.
[7]徐兵河.复发转移乳腺癌的化学治疗[J].中国实用内科杂志,2007,27：24.
[8]Vahdat LT, Tomas E, Li R, et al. Phase III trial of ixabepilone plus capecitabine compared to capecitabine alone in patients with mestastatic breast cancer(MBC) previously treated or resistant to an anthracycline and resistant to taxanes[J].Proc Am Soc Clin Oncol, 2007,25(18s):33s.
[9]Rakha EA,E1 Sayed ME,Green AR Prognostic makers in triple-negative breast cancer[J].Cancer,2007,109:25.
[10]Nielen TO,Hsu FD,Jensen K,et al.Immunolistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma[J].Clin Cancer Res,2004,10:5367-5374.
[11]Banerjee S,Reis Filho JS,Ashley S,et al.Basal-like breast carcinomas:clinical outcome and response to chemotherapy[J] J Clin Pathol,2006,59:729-735.
[12]Dent R,Trudeau M,Pritchard KI,et al.Triple-negative breast cancer:clinical features and patterns of recurrence[J].Clin Cancer Res,2007,13(15):4429-4434.
[13]李庆,范晓磊.中药抗肿瘤的研究进展[J].中国微生态学杂志,2007,19(3)：317-318.
[14]潘启超,胥彬主编.肿瘤药理学与化疗学第二版[M].河南医科大学出版社,郑州,2000;315.
[15]李厚伟,张妍,许超千,等.中药HB对喉癌Hep22细胞的抑制作用及其机制研究[J].哈尔滨医科大学学报,2001,35(4)：261-262.
[16]刘国清,田秉漳,皮执民,等.蜈蚣油性提取液对肝癌细胞增殖的影响[J].中国现代医学杂志,2002,12(4)：55-56.
[17]曾红,张国刚,程巨龙.蜈蚣中抗癌活性成分的提取[J].湖南中医志,2004,20(5)：57-58.
[18]刘细平,钟德玝.蜈蚣提取液对裸鼠移植肝癌抑癌作用及机制的研究.[J].中国普通外科杂志,2010,19(2)：164-168.
[19]Gygi SP, Corthals GL, Zhang Y, et al. Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology[J].Proc Natl Acad Sci U S A, 2000,97(17):9390-9395
[20]Washburn MP, Wolters D, Yates JR, et al. Large-scale analysis of the yeast proteome by multidimensional protein identification technology[J].Nat Biotechnol, 2001,19(3):242-247
[21]Gorg A, Weiss W, and Dunn MJ. Current two-dimensional electrophoresis technology for proteomics[J].Proteomics,2004,4(12):3665-3685
[22]Hancock WS, Wu SL, Shieh P, et al. The challenges of developing a sound proteomics strategy[J].Proteomics,2002,2(4):352-359
[23]Rabilloud T, Blisnick T, Heller M, et al. Analysis of membrane proteins by two-dimensional electrophoresis:comparison of the proteins extracted from normal or Plasmodium falciparum-infected erythrocyte ghosts[J].Electrophoresis,1999, 20(18):3603-3610
[24]Wissing J, Heim S, Flohe L, et al. Enrichment of hydrophobic proteins via Triton X-114 phase partitioning and hydroxyapatite column chromatography for mass spectrometry[J].Electrophoresis,2000,21(13):2589-2593
[25]Pierce WM and Cai J. Applications of mass spectrometry in proteomics[J].Contrib Nephrol,2004,141:40-58
[26]Aebersold R and Mann M. Mass spectrometry-based proteomics[J].Nature, 2003,422(6928):198-207
[27]司秋菊,王鑫国,白霞,等.蜈蚣对动脉粥样硬化家兔血液流变学的影响[J].中国老年学杂志,2004,24(9)：831-833.
[28]焦波,娄红祥,王东兴,等.蜈蚣提取液对小鼠精原细胞的作用[J].山东医科大学学报,1999,37(4)：358.
[29]司徒镇强,吴军正.细胞培养[M].西安：世界图书出版公司,2004,1-37.
[30]赵满仓,魏文清等.MTT法抗肿瘤药敏试验影响因素的探讨[M].临床肿瘤学杂志,2009,14(4)：306-308.
[31]Khar A,Alia AM,Pardhasaradhi BV,et al.Induction of stress recsponse renders human tumor cell lines resistant to curcumin-mediated apoptosis:Role of reactive oxygen intermediates[J].Cell Stress Chaperones,2001;694:368-7.
[32]R.A Weinberg著,詹启敏,刘芝华主译.癌生物学[M].北京科学出版社,2009,716-717.
[33]Henrik Mueller, Matthias U Kassack, Michael Wiese. Comparison of the usefulness of the MTT, ATP, and ealcein assays to predict the potency of cytotoxic agents in various human cancer cell lines[J]. J Biomol Screen,2004,9:506-515.
[34]Tsujimoto Y, Finger LR, Yunis J, et al. Cloning of the chromosome breakpoint of neop lastic B-cell with the t (14; 18) chromosome translocation[J]. Science,1984,226(4678):1097-1099.
[35]Callagy GM, Pharoah PD, Pinder SE. bcl-2 is aprognostic marker in breast cancer independently of the nottingham prognostic index[J]. Clin Cancer Res,2006, 12:2468-2475.
[36]Moreno A, Figueras A, Lloveras B, etal。Apoptosis in ductal carcinoma in situ of the breast [J]1 Breast J,2001,7(4):245-248.
[37]YANG LJ, WANG WL. Establishment of the hepatoma cells which express Bax protein stably and highly and observation of its apoptotic phenomena [J]. Di-si Junyi Daxue Xuebao(J Fourth Mil Med Univ),2002,23(5):455-458.
[38]于冰,孙治君.凋亡相关基因bc122、bax、bad与乳腺癌[J].中国普外基础与临床杂志,2007,14(6)：739-741.
[39]Morizane Y,Honda R,Fukami K,et al.X-linked inhibitor of apoptosis functions as ubiquitin ligase to ward mature caspase-9 and cytosolic Smac/ DIABLO[J] J Biochem (Tokyo),2005,137:125-132.
[40]Yamaguchi H, Paranawit hana SR, Lee MW,et al. Epot hilone B analogue (BMS-247550)-mediated cytotoxicity through induction of Bax conformational change in human breast cancer cells [J].Cancer Res,2002; 62 (2):466.
[41]薛敬礼,李小民,等。人乳腺癌MDA-MB-231细胞裸鼠移植瘤模型的建立及生物学特性研究[J]。Sichuan Journal of Zoology,2006,25 (13): 635-637
[42]孙金中,孙圣荣,等。三种建立小鼠乳腺癌移植模型方法的比较[J]武汉大学学报,2006,27(3)：335-337
[43]Iwanuma Y,Chen F, Egilmez N,et al.Antitumor immune response of human periperal blood lymphocytes coengrafted with tumor into severe combined immmunodeficient mice [J].Cancer Res,1997,57(14):2937-2942.
[44]宋萍,王学美,谢爽,等.鲜壁虎冻干粉抑制H22肿瘤血管生成机理的实验研究[J].中国中西医结合杂志,2006,26(1)：58-62.
[45]孙纪元,朱妙章,王四旺,等.苦马豆素对乳腺癌细胞在体内外生长的抑制作用[J].华西药学杂志,2006,21(3)：221-224.
[46]叶燕丽,周听熙,王莲桂.裸裸鼠的繁殖及在肿瘤学中的应用[J].实验动物科学与管理,2005,22：6-8.
[47]Celinski SA,Fisher WE, Amaya F. etal. Somatostatin receptor gene transfer inhibits established pancreatic cancer xenografts[J]J Surg Res,2003, 115:41-47.
[48]Jean M. Angiogenesis:A boost for tumor starvation[J].Science,2003 301:452-454
[49]Lin A Y,Brophy N, Fisher GA,etal. Phase Ⅱ study of thalidomide in patient s with unresectable hepatocellular carcinoma[J].Cancer,2005,103:119-125
[50]黑振宇,王鲁,金惠铭VEGF与原发性肝癌血管新生关系的研究进展[J].中国微循环,2005,9(4)：292-2
[51]Lenz HJ. Antiangiogenic agents in cancer therapy[J].Oncology(Williston Park),2005,19(4 Suppl 3):17-25
[52]邹奇飞,张峰.肝癌中血管生成素2和血管内皮生长因子的表达及其临床意义[J].江苏医药,2006,32(5)：436-438
[53]Moon WS, Rhyu KH, Kang MJ, et al. Overexpression of VEGF and angiopoietin 2:a key to high vascularit y of hepatocellular carcinoma[J]. Mod Pathol, 2003,16(6):552-557
[54]马铁祥,王志明.血管生成素-2,VEGF和bFGF在人乳腺癌中表达及意义[J].医学临床研究,2006,23(3)：336-339
[55]Pichilue P, Chavez JC, LaManna JC, e t a l. Hypoxic regulation of angiopoietin-2 expression in endothelial cells [J]J Biol Chem,2003,279(13): 12171-12180
[56]Sinha P, Poland J, Kohl S, et al. Study of the development of chemoresistance in melanoma cell lines using proteome analysis. Electrophoresis, 2003,24(14):2386-2404.
[57]Rutherford SL,Lindquist S. HSP90 as a capacitor for morphological evolution[J]. Nature,1998,396 (6709):3362342.
[58]Pandey P,Saleh A,Nakazawa A, et al. Negative regulation of cytoehrome c2mediated oligomerization of Apaf21and activation of proeaspase-9 by heat shock protein 90 [J]. EMBO J,2000,19(16):43104322
[59]Solit DB, Rosen N. Hsp90:a novel target for cancer therapy. Curr Top Med Chem.2006;6(11):1205-1214.
[60]Basso AD, Solit DB, Munster PN, Rosen N. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene.2002;21(8):1159-1166.
[61]Armstrong RN.Structure,catalytic mechanism,and evolution of the glutathione transferases[J].Chem Res Toxicol,1997,10:2
[62]Board PQCoggan M,Chelvanayagam G,et al.Identification, Characterization and crystal structure of the Omega class Glutathione transferases[J]J Biol Chem.2000,275,24798-24806
[61]Meyer DJ,Coles B,Pemble SE,et al.Theta,a new class of glutathione transferases purified from rat and man[J].BiochemJ,1991,274(Pt2):409-414
[64]Wilce MCJ,Parker MW.Structure and function of glutathione S-transferases[J].Biochim Biophys Acta,1994,1205,1-18
[65]Coggan M,Whitbread L,Whitington A et al.Structure and organization of the human Theta-class glutathione S-transferase and D-dopachrome tautomerase gene complex[J].Biochem J,1998,334,617-623
[66]Hayes J D,Pulford DJ.The glutathione S-transferases upergene family:regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance[J].Crit Rev Biochem Mot Biol,1995, 30(6):445-600
[67]Nooter K,de la Riviere GB,Klijn J,et al.Multidrug resistance protein in recurrent breast cancer[J].Lancet,1997,349(9069):1885-1886
[68]Kinloeh A, Tamer V, Wait R, et al. Identification of eitmllinated alpha-
enolase as a candidate autoantigen in rheumatoid arthritis[J]. Arthritis Res Ther.2005,7(6):R1421—1429
[69]Ran G, Adamus G Cellular targets of anti-alpha-enolase autoanti-bodies of patients with autoimmune retinopaifiy[J]. JAutalmmun,2004,23(2):161—167.
[70]Nahm D H. Lee K H, Shim JY Identification of alpha-enolase as an autoanfign asstmiated with sever asthma[J]. J Allergy ClinIhmunol,2006,118(2): 376-381
[71]Ghosh A K, Steele R. Ray R B C-mye promoter-binding pmtein 1 (MBP-1) regulates prestate cancer eall growth hy inhibiting MAPK pathway[J]J Bial Chem,2005,280(14):14325—14330
[72]EjesharK. Krtma C, Caren H, et al.Introduction of in vitro transcribed EN01 mRNA into neuroblastama ceUs inducez cell death [J]BMC Cancer.2005, 5(12。):161—174
[73]Takashima M, KuramJtsu Y, Yokoyama Y. at al Overexpresaion Of alpha enolase in hepatitis C virus-related hepatocellular carcinoma:association with tumor progression as determined by protaomie analysis[J], Proteomics.2005,5(6): 1686—1692.
[74]Chang G C, Liu K J, Hsieh C L, et al Identification of alpha enolase as an autoantigen in lung cancer:its overexpression is assoeiatedwith clinical outcomes[J]. Clin CancerRes,2006,12(19):5746-5754
[75]DiMauro, S.; Miranda, A. F.; Sakoda, S.; Schon, E. A.; Servidei, S.; Shanske, S.; Zeviani, M.:Metabolic myopathies. Am. J. Med. Genet.25:635-651,1986.
[76]Pretsch, W.; Favor, J.:A precise localization of a mouse gene encoding increased phosphoglycerate mutase activity (Pgamlel) on chromosome 19. Mammalian Genome 7:619 only,1996.
[77]Sultana R, Perluigi M, Newman SF Redox proteomic analysis of carbonylated brain proteins in mild cognitive impairment and early Alzheimer's disease.Antioxid Redox Signal.2010 Mar; 12(3):327-36.
[78]Huang LJ, Chen SX, Huang Y.-Proteomics-based identification of secreted protein dihydrodiol dehydrogenase as a novel serum markers of non-small cell lung cancer.Lung Cancer.2006 Oct;54(1):87-94.
[79]Luo Y, Li Y, Lin C:Comparative proteome analysis of splenic lymphocytes in senescence-accelerated mice.Gerontology.2009;55(5):559-69.
[80]Gao YL, Liu P, Sun HL:Proteomic analysis of rat astrocytes and C6 glioma cells] Zhonghua Yi Xue Za Zhi.2007 Dec 25;87(48):3421-4.
[81]Zhang YQ, Li W, Wang GJ:Effect of low dose radiation on human bone marrow mesenchymal stem cells by using proteomic analysis]Zhongguo Shi Yan Xue Ye Xue Za Zhi.2008 Feb;16(1):151-5.
[82]. Turhani D, Krapfenbauer K, Thurnher D:Identification of differentially expressed, tumor-associated proteins in oral squamous cell carcinoma by proteomic analysis.Electrophoresis.2006 Apr;27(7):1417-23.
[83]Lu F, Xia Q, Ma Y:Serum proteomic-based analysis for the identification of a potential serological marker for autoimmune hepatitis.Biochem Biophys Res Commun.2008 Mar 7;367(2):284-90. Epub 2007 Dec 26.
[84]Zephir H, Almeras L, El Behi M:Diversified serum IgG response involving non-myelin CNS proteins during experimental autoimmune encephalomyelitis. J Neuroimmunol.2006 Oct; 179(1-2):53-64.
[85]Michael, D.S,Elmar, N:Immunopharmacology2000,47,163.
[86]Pimkin M, Markham GD.:Inosine 5'-monophosphate dehydrogenase.Adv Enzymol Relat Areas Mol Biol.2009;76:1-53. Review.
[87]Nair V, Shu Q:Inosine monophosphate dehydrogenase as a probe in antiviral drug discovery.Antivir Chem Chemother.2007;18(5):245-58. Review.
[88]Moosavi MA, Yazdanparast R:Distinct MAPK signaling pathways, p21 up-regulation and caspase-mediated p21 cleavage establishes the fate of U937 cells exposed to 3-hydrogenkwadaphnin:differentiation versus apoptosis.Toxicol Appl Pharmacol.2008 Jul 1;230(1):86-96.
[89]Chen L, Pankiewicz KW:Recent development of IMP dehydrogenase inhibitors for the treatment of cancer.Curr Opin Drug Discov Devel.2007 Jul;10(4):403-12. Review.
[90]Kagaya H, Miura M, Saito M:Correlation of IMPDH1 Gene Polymorphisms with Subclinical Acute Rejection and Mycophenolic Acid Exposure Parameters on Day 28 after Renal Transplantation.Basic Clin Pharmacol Toxicol. 2010 Feb 2.
[91]Nakanishi T, Morokata T, Kubo K:Effect of the inosine 5'-monophosphate dehydrogenase inhibitor BMS-566419 on rat cardiac allograft rejection.Int Immunopharmacol.2010 Jan;10(1):91-7. Epub 2009 Oct 18.
[92]Gareth D,Bing ZHANGMetabolic Syndrome X Gene Expression and Protential Treating Using Herbal Medicine[M].Annual Report 2002-2003,Human Nutrition Unit,Sydney University
[93]Brodie AE,Reed DJ.Reversible oxidation of glyceraldehyde-3-dehydrogenase thiols in human lung carcinoma cell by hydrogen peroxidase[J]. Biochem Biophs Res Commun,1987,148:120
[94]Tajima H,Tsuchiya K,Yamada M,et al.Over-expression of GAPDH induces apoptosis in COS-7 cells transfected with colned GAPDH cDNAs [J].Neuroreport, 1999,10(10):2029-2033
[95]Sheline CT,Choi DW,Neuronal death in cultured murine cortical cells in induced by inhibition of GAPDH and triosephosphate isomerase[J].Neurobiol Dis,1998,5(1):45-54
[96]Shashidharan P,Chalmers Redmen RM,Carlile GW,et al.Nuclear translocation of GAPDH-GFP fusion protein during apoptosis[J].Neuroreport,1999,10 (5):1149-1153
[97]Ishitani R,Tanaka M,Sunaga K,et al.Nuclear localization of over-expressed glyceral dehydes-3-phosphatedehydrogenase in cultured cerebellar neurons undergoing apoptosis [J].Mol Pharmacol,1998,53(4):701-707
[98]Ikeguchi M,Hirooka Y.Quantiative analysis of apoptasis-related gene expression in epatocellular carcinoma[J].Cancer,2002,95(9):1938-1945
[99]Sirover MA.New insight into an old protein:the functional diversity of ammalian leraldehyde 3-phosphate dehyrogeenase[J].Biochim Biophys Acta,1999, 1432(2):159-184
[100]Kawamoto RM,Caswell AH..Autophosphorylation of glyceraldehydes-phosphate dehydrogenase and phosphorylation of protein from skeletal muscle microsomes[J].Biochemistry,1986,25:656-661
[101]Crespo E,Macias M,Pozo D,et al.Melatonin inhibits expression of the inducible NO synthase Ⅱ in liver and lung and prevents endotoxemia in lipopolysaccharide-induced multiple organ dysfunction syndrome in rats [J].FASEB J,1999,13(12):1537-1546
[102]Beckett GJ,Hates PC,Hussey AT,et al.Plasma glutation Stranferases measurements in patients with alcoholic cirrhosis[J].Clin Chem Acta,1987,169:85
[103]Sanchez A,Alvarez AM,Pagan R,et al.Fibronectin regulates morphology,cell organization and gene expression of rat fetal hepatocytes in primary culture[J].J Hepatol,2000;32(2):242-250
[104]Jung R, Kruger W, Hosch S, et al.Specificity of reverse transcriptase polymerase chain reaction assays designed for the detection of circulating cancer cells is influenced by cytokines in vivo and in vitro [J].Br J Cancer,1998,78 (9): 1194-1198
[105]5Ball BL,Faouzi S,Boussraie L,et al.Extracellular matrix composition and integrin expression in early hepatocarcinogenesis in human cirrhotic liver[J]J Pathol,1997,181:330-337
[106]傅勇,苏勤,刘彦仿,等.层粘连蛋白诱导体外生长的乳腺癌细胞表达细胞角蛋白19[J].肝脏,2002,7(3)：162-164
[107]Yui S, Nakatani Y, Mikami M.Calprotectin (S100A8/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis-inducing activity.Biol Pharm Bull.2003 Jun;26(6):753-60. Review.
[108]Perera C, McNeil HP, Geczy CL.S100 Calgranulins in inflammatory arthritis.Immunol Cell Biol.2010 Jan;88(1):41-9. Epub 2009 Nov 24. Review.
[109]Halayko AJ, Ghavami S.S100A8/A9:a mediator of severe asthma pathogenesis and morbidity?Can J PhysiolPharmacol.2009Oct;87(10):743-55. Review.
[110]Sroussi HY, Lu Y, Zhang QL.S100A8 and S100A9 inhibit neutrophil oxidative metabolism in-vitro:Involvement of adenosine metabolites. Free Radic Res.2010 Apr;44(4):389-96.
[111]Zhu H, Zeng S, Zeng L. Significance and expression of S100A9 and NMP238 in cervical carcinoma tissues with different concurrent chemoradiotherapy sensitivities.]Zhong Nan Da Xue Xue Bao Yi Xue Ban.2010 Jan;35(1):45-51. Chinese.
[112]Ju W, Yoo BC, Kim IJ.Identification of genes with differential expression in chemoresistant epithelial ovarian cancer using high-density oligonucleotide microarrays.Oncol Res.2009;18(2-3):47-56.
[113]Qin F, Song Y, Li Z.S100A8/A9 Induces Apoptosis and Inhibits Metastasis of CasKi Human Cervical Cancer Cells.Pathol Oncol Res.2009 Dec 3.
[114]Mehul B, Bernard D, Brouard M. Hege Influence of calcium on the proteolytic degradation of the calmodulin-like skin protein (calmodulin-like protein 5) in psoriatic epidermis.Exp Dermatol.2006 Jun;15(6):469-77.
[115]Mehul B, Bernard D, Schmidt R.Calmodulin-like skin protein:a new marker of keratinocyte differentiation.J Invest Dermatol.2001 Jun;116(6):905-9.
[116]Saussez S, Cucu DR, Decaestecker C,et al.Galectin 7(p53-Induced Gene 1):A New Prognostic Predictor of Recurrence and Survival in Stage IV Hypopharyngeal Cancer[J]. Annals of Surgical Oncology,2006,13(7):999-1009
[117]I Saussez S, Decaestecker C, Lorfevre F, ncreased expression and altered intracellular distribution of adhesion/growth-regulatory lectins galectins-1 and-7 during tumour progression in hypopharyngeal and Iaryngeal squamous cell carcinomas.Histopathology.2008 Mar;52(4):483-93.
[118]Demers M, Couillard J, Giglia-Mari G, Increased galectin-7 gene expression in lymphoma cells is under the control of DNA methylation.Biochem Biophys Res Commun.2009 Sep 25;387(3):425-9.
[119]Klima J, Lacina L, Dvorankova B,Differential regulation of galectin expression/reactivity during wound healing in porcine skin and in cultures of epidermal cells with functional impact on migration.Physiol Res.2009;58(6):873-84.
[120]Cada Z, Chovanec M, Smetana K, Galectin-7:will the lectin's activity establish clinical correlations in head and neck squamous cell and basal cell carcinomas? Histol Histopathol.2009 Jan;24(1):41-8.
[121]Than TH, Swethadri GK, Wong J,Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators.Singapore Med J.2008 Apr;49(4):333-8.
[122]Ghavami S, Chitayat S, Hashemi M,S100A8/A9:a Janus-faced molecule in cancer therapy and tumorgenesis.Eur J Pharmacol.2009 Dec 25;625(1-3):73-83.
[123]Ehrchen JM, Sunderkotter C, Foell D, The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer.J Leukoc Biol.2009 Sep;86(3):557-66. Epub 2009 May 18. Review.
[124]Li HL, Chen DD,Li XH, et al. Changes of NF-kB, p53, bcl-2 and caspase in apoptosis induced by JTE-22 in human gastric adenocarcinoma cell line AGS cells: role of reactive oxygen species [J]. World J Gastroenterol,2002,8:431-435.
[125]Saleh HA, Jin B, Barnwell J,Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules.Diagn Pathol. 2010 Jan 26;5:9.
[126]Saloustros E, Mavroudis D.Cytokeratin 19-positive circulating tumor cells in early breast cancer prognosis.Future Oncol.2010 Feb;6(2):209-19.
[127]Zhang X, Chen SB, Chen JX,CK19 mRNA expression in the bone marrow of patients with esophageal squamous cell carcinoma and its clinical significance.Dis Esophagus.2010 Jan 20.
[128]Dos Santos JN, Oliveira GQ, Gurgel CA,Altered expression of cytokeratins in primary, recurrent and syndrome keratocystic odontogenic tumors.J Mol Histol.2009 Aug;40(4):269-75.
[129]Leffler H,Carlsson S,Hedlund M,et al.Introduction to galectins[J]. lycoconj. J.2004,19:433-440
[130]Liu FT,Rabinovich GA.Galectins as modulators of tumour progression[J].Nat Rev Cancer,2005,5(1):29-41
[131]Saussez S, Kiss R. Galectin-7 Review[J].Cell Mol Life Sci 2006,63:686-97
[132]Cao Z, Wu HK, Bruce A, et al.Detection of differentially expressed genes in healing mouse corneas,using cDNA microarrays.Invest[J].Ophthalmol. Vis.Sci.2002,43:2897-2904
[133]Cao Z, Said N, Amin S,et al.Galectins-3 and -7,but not galectin-l,play a role in reepithelialization of wounds[J].J.Biol.Chem.2002,277:42299-42305
[134]Cao Z, Said N, Wu HK, et al. Galectin-7 as a potential mediator of corneal epithelial cell migration.Arch[J].Ophthalmol.2003,121:82-86
[135]Pr Zhu H, Pei HP, Zeng S,ofiling protein markers associated with the sensitivity to concurrent chemoradiotherapy in human cervical carcinoma. J Proteome Res.2009 Aug;8(8):3969-76.
[1]韩双红.蜈蚣的研究进展[J].天津药学,2002,14(5)：13-15.
[2]刘峰.蜈蚣的临床应用及毒性研究[J].广西中医药,1999,22(4)：52-53.
[3]杨永华,张水寒,徐琳本,等.僵蚕、蜈蚣提取工艺的研究[J].中国中药杂志,2001,26(9)：599-601.
[4]许鸣镝,柳雪枚.蜈蚣碱性蛋白SSmp-d的分离纯化及其部分理化性质的鉴定[J].生物化学杂志,1997,13(5)：586-591.
[5]曲爱兵,赵维成,梁良,等.蜈蚣组织提取物抗肿瘤活性的初步研究[J].实用肿瘤学杂志,2003,17(1)：29-30.
[6]迟程.墨江蜈蚣和少棘蜈蚣蚣总油脂化学成分比较[J].中草药,1992,23(2)：104.
[7]方红,邓芬,严宜昌,等.黑头蜈蚣的化学成分[J].中药材,1999,22(5)：226-228.
[8]方红,邓芬,严宜昌,等.多棘蜈蚣化学成分的研究[J].中国医学杂志,1997,32(4);202-203.
[9]张保国,张大禄.动物药[M].北京：中国医药科技出版社,2003,875.
[10]肖培根.新编中药志(第四卷)[M].北京：化学工业出版社,2002,330.
[11]周莉莉,黄迎春,任超.蜈蚣醇提取物和水提取物部分药理作用比较[J].时珍国医国药,2008,19(11)：2697-8.
[12]迟程,罗天浩.蜈蚣毒性与用量的探讨[J].中国中药杂志,1995,15(6)：90-91.
[13]刘峰.蜈蚣的临床应用及其毒性研究[J].广西中医药,1999,22(4)：52-53.
[14]宋建徽,孟祥琴,王永利.蜈蚣提取液的中枢抑制作用及急性毒性[J].河北中医学院学报,1995,16(2)：91-92.
[15]韩双红.蜈蚣的研究进展[J].天津药学2002,14(5)：13-15.
[16]迟程,舒晔,迟萍.墨江蜈蚣和少棘蜈蚣抗惊厥药效学实验研究[J].云南中医学院学报,1992,15(1)：23-24.
[17]陈红琳,李小莉,甘明.墨江蜈蚣的药理作用[J].湖北中医杂志,2003,25(1)：501.
[18]司秋菊,王鑫国,白霞,等.蜈蚣对动脉粥样硬化家兔血液流变学的影响[J].中国老年学杂志,2004,24(9)：831-833.
[19]司秋菊,王亚利,王鑫国,等.蜈蚣有效成分抗心肌缺血作用的研究[J].河北中 医药学报,2001,16(2)：1-3.
[20]司秋菊,王亚利,王鑫国,等.蜈蚣对心肌缺血性损伤小鼠NO及iNOS的影响[J].山东中医杂志,2004,23(8)：492-493.
[21]司秋菊,王鑫国,王亚利,等.蜈蚣对动脉粥样硬化家兔血管内皮细胞功能的影响[J].中药药理与临床,2002,18(6)：28-30.
[22]张艳慧,司秋菊,王鑫国.蜈蚣抗家兔动脉粥样硬化的实验研究[J].中药药理与临床2005；21(1)：26-27.
[23]王亚利,司秋菊,王鑫国,等.蜈蚣对动脉粥样硬化家兔血管平滑肌细胞周期及c-myc基因表达的影响[J].中药药床,2001,17(6)：28-29.
[24]张明泉,王亚利,温瑞书,等.蜈蚣提取液对大鼠心脏血流动力学的作用研究[J].河北中医,2004,26(9)：716-717.
[25]毛小平,陈子君,毛晓建,等.蜈蚣的部分药理研究[J].云南中医学院学报,1999,22(3)：1-4.
[26]曾红,张国刚,程巨龙.蜈蚣中抗癌活性成分的提取[J].湖南中医杂志,2004,20(5)：57-58.
[27]焦波,娄红祥,王东兴,等.蜈蚣提取液对小鼠精原细胞的作用[J].山东医科大学学报,1999,37(4)：358.
[28]李风云,陈浩然,张蓄兰,等.中药制剂抗肿瘤作用的实验研究[J].中医药学报,1999,27(5)：57.
[29]刘德贵,苗艳波,张铁光,等.简述有毒动物药的抗肿瘤作用临床研究[J].吉林中医药,1998,18(6)：61.
[30]李厚伟,张妍,许超千,等.中药HB对喉癌Hep22细胞的抑制作用及其机制研究[J].哈尔滨医科大学学报,2001,35(4)：261-262.
[31]刘国清,田秉漳,皮执民,等.蜈蚣油性提取液对肝癌细胞增殖的影响[J].中国现代医学杂志,2002,12(4)：55-56.
[32]冉泳禄,吴刚,王金焕,等.墨江蜈蚣与少棘蜈蚣的比较研究Ⅱ[J].动物学研究,1996,17(1)：79.
[33]贺巍,叶海英.中药蜈蚣的研究进展[J].中药材,2002,25(2)：152-155.
[34]毛小平,陈子珺,毛晓健,等.蜈蚣的部分药理研究[J].云南中医学院学 报,1999,22(3)：1-3.
[35]李小莉,陈红林,甘民.不同品种蜈蚣的抗炎、镇痛作用[J].中国中药杂志,1996,21(8)：498.
[36]陈红琳,李小莉,甘明.墨江蜈蚣的药理作用[J].湖北中医杂志,2003,25(1)：50-51.
[37]梁洁,黄华营.药用蜈蚣的化学成分及药理活性研究近况[J].广西中医药[J]2005,28(4)：6-7.
[38]张维文,罗健东,张贵平.蜈蚣水提物对动物消化功能的增强作用.[J].中药材,1999,22(10)：518-519.
[39]朱步先.朱良春用药经验[M].上海：上海中医学院出版社,1989 120.
[40]王玉芬,韩双红,曲树明,等.蜈蚣延缓衰老作用的研究[J].中国中药杂志,1994,19(11)：685-687.
[41]任丽虹,郝立君,段国新,等.五倍子、蜈蚣对瘢痕疙瘩成纤维细胞增殖和胶原合成的影响[J].实用美容整形外科杂志,2003,14(6)：324-327.
[42]韩双红,王玉芬,赵泰,等.均肾舒冲剂药理作用的研究[J].中草药,1999,30(4)：282.
[43]方红,邓芬.蜈蚣药材中毒成分组织胺的含量测定[J].中草药,1997,28(8)：472-473.
[44]陶红.牵正蜈蚣散治疗神经系统疾病328例临床体会[J].湖南中医杂志,1990,6(1)：216.
[45]伍玉元.蜈蚣粉致急性肝功能损害2例[J].中国中药杂志,1994,19(1)：50.
[46]赵鹏俊,邹永祥.口服蜈蚣粉致急性肾功能衰竭死亡1例[J].中国中药杂志,1998,23(2)：117.
[47]肖贻纯.蜈蚣、全蝎致神经中毒1例[J].中国中药杂志,1996,21(10)：634.
[48]余圣龙.生蜈蚣致过敏[J].中国中药志,1989,14(5)：56.
[49]陈听.蜈蚣过敏1例[J].四川中医,1997,15(10)：32.
[50]郭志达,吉小莉,宋建贞,等.中药蜈蚣对大鼠心脏毒性作用的初步研究[J].中国临床药理学与治疗学,2000；5(3)：278.
[51]邓芬,方红,王克勤.中药蜈蚣毒溶血活性试验[J].中药材,1997,20(1)：36-37.
[52]虞国茂,沈康.中药蜈蚣对小鼠胚胎发育的影响[J].解剖学杂志,1994,17(1)：56-59.
[53]迟程,罗天浩.蜈蚣毒性与用量的探讨[J].中国中药杂志,1995,15(6)：90-91.
[54]刘峰.蜈蚣的临床应用及其毒性研究[J].广西中医药,1999,22(4)：52-53.
[55]宋建徽,孟祥琴,王永利.蜈蚣提取液的中枢抑制作用及急性毒性[J].河北中医学院学报,1995,16(2)：91-92.
[56]李小莉,陈红琳,甘民.不同品种蜈蚣的抗炎、镇痛作用[J].中国中药杂志,1996,21(8)：498-499.
[57]韩双红.蜈蚣的研究进展[J].天津药学2002,14(5)： 13-15.
[1]Law RenceW,Norton,李芬芳,等.美国乳腺癌治疗现状[J].陕西肿瘤医学,2000,8(2)：123.
[2]Chow LWC,LooWTY. The differential effects of cyclophosphamide,ep irubicinand5-fluorouracil on apoptotic marker (CPP-32), pro-ap-optotic protein (p21waf-1) and anti-apoptotic protein (bcl-2) in breast cancer cells[J]. Breast Cancer Res Treat,2003,80 (3):239-244.
[3]董志伟,乔友林等.中国癌症高发现场报告[J].中国肿瘤,2009,18(1)：4-9.
[4]陈孝平,石应康,邱贵兴,主编.外科学[M].北京：人民卫生出版社,2005.439.
[5]常卫华,王留兴等.乳腺癌分子靶向治疗的进展与展望[J].肿瘤基础与临床,2009,22(3)：270-271.
[6]Jacobs JR,Bovasso GB. Early and chronic stress and their relation to breast cancer[J]. PsycholMed,2004,30 (3):669-678.
[7]朱珍,张凤春.晚期乳腺癌的化疗进展[J].现代肿瘤医学,2009,17(6)：1179-1181.
[8]徐兵河.复发转移乳腺癌的化学治疗[J].中国实用内科杂志,2007,27：24.
[9]商宏恺,童晓文.乳腺癌手术治疗的演变[M].中国实用妇产与产科杂志,2008,24(11)：808-810.
[10]HalstedWS. The results of operations for cancer of breast performed at the Johns Hopkins hospital from June1889 to January1889 [J].Joh Hop Bul,1894,4:294.
[11]Urban JA,Baker HW. Radical mastectomy with en bloc resection of the Intelmammary lymph node chain:a new procedure for primary operable cancer of the breast[J]. Cancer,1952,5 (5):992-1008.
[12]Fisher B, Jeong J H,Anderson S,et al.Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation[J]. N Engl J Med,2002,347 (8):567.
[13]王先明.乳腺癌手术治疗的历史演变与现代进展[J].中国现代手术学杂志,2003,7(6)：467-471.
[14]Smit JJ, SchinkelAH,Oude Elferink RPJ, et al. Homozygous disruption of the murine mdrz pglycop rotein gene leads to a comp lete absence of phospholip id from bile and to liver disease[J]. Cell,1993,75(3):451-462.
[15]Veronesi U, Banfi A, Salvadori B, et al. Breast conservation is the treatment of choice in small breast cancer:long-term results of a randomized trial. Eur J Cancer,1990,26:668-670.
[16]Fisher B, Anderson S, Redmond CK, et al. Reanalysis and result s after 12 years of follow-up in a randomized clinical trial comparing total mastectomy wit h lumpectomy wit h orwit hout irradiation in the treatment of breast cancer [J]. NEngl J Med,1995; 333 (22):1456-1461
[17]National Surgical Adjuvant Breast and Bowel Project (NSABP).Progress Report [R]. July 1998:31-39.
[18]Sarrazin D, Arriagada R, Contesso G, et al. Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer. Radiother Oncol,1989,14:177-184.
[19]Cutuli B,Nir CCS,Lafontan BD,et al.Brast-conserving therapy for ductal carcinoma in situ of the Breast:the French Cancer centers experience[J].Int J Radia Oncol Biol Phys,2002,53:868-879.
[20]Hiotic K,Ye W, Sposto R,et al.Predictors of breast conservation the rapy size is not all thatmatters[J]. Cancer,2005,103(5):892-899.
[21]叶再元,蒋劲松.乳腺癌外科治疗新进展[J].现代实用医学,2005,17(12)：730-732.
[22]郭小毛,梅欣等.局部晚期乳腺癌的治疗进展[J].中国癌症杂志,2006,16(6)：409-416.
[23]Reed J, Rosman M, Verbanac KM, et al. Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer:10-year analysis of patients enrolled in the prospective East Carolina University/Anne Arundel Medical Center Sentinel Node Multicenter Study[J]. J Am Coll Surg,2009,208(3):333-340.
[24]Sato K, Shigenaga R. Sentinel lymph node biopsy for breast cancer[J]. J Surg Oncol,2007,96:322-329.
[25]邵志敏,沈镇宙.21世纪乳腺癌治疗的展望[M].中国癌症杂志,2005,15(5)：405-407
[26]Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemot-herapy. Danish Breast Cancer Cooperative Group 82b Trial [J]. N Engl J Med,
1997; 337 (14):949-955.
[27]Whelan TJ,J ulian J,Wright J,et al.Does locoregional radiation therapy improve survival in breast cancer?A meta-analysis A meta-analysis [J] J Clin Oncol,2000; 18 (6):1220-1229.
[28]Recht A,Edge SB,Solin LJ,et al.Postmastectomy radiotherapy:clinical practice guidelines of the American Society of Clinical Oncology [J]. J Clin Oncol,2001;19(5):1539-1569.
[29]于世英.放疗在乳腺癌治疗中作用[J].临床外科杂志,2000,8(5)：261.
[30]薛军,程晶等.不同放化疗模式治疗局部晚期乳腺癌的疗效分析[J].肿瘤防治研究,2009,36(10)：876-878.
[31]余子豪,乳腺癌.[M]//殷蔚伯,谷铣之.肿瘤放射治疗学.3版.北京：中国协和医科大学出版社,2002：1077-1078.
[32]Early Breat Cancer TrialistsI Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:An overview of the randomised trials [J]. Lancet,2005, 365 (9742):1687-1717.
[33]Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide methotrexate, and fluorouracil in node -positive breast cancer the results of 20 years of follow-up [J]. N Engl J Med,1995,332 (14):901.
[34]Bonadonna G, Moliterni A, Zambetti M, et al.30 years follow up of randomized studies of adjuvant CMF in operable breast cancer, cohort study[J]. BMJ 2005,330:217.
[35]Early Breast Cancer Trialists's Collaborative Group. Multi-agent chemotherapy for early breast cancer DB/CD]. Cochrane Database Syst Rev,2002, (1):CD000487.
[36]Poole CJ, Earl HM, Hiller L, et al. Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as adjuvant therapy for early breast cancer [J].N Engl J Med,2006,355 (18):1851-1862.
[37]Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer[J].J Clin Oncol,2003,21 (6):976-983.
[38]Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after Doxorubicin plus Cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer:Results from NSABP B-28 [J]. J Clin Oncol,2005,23 (16): 3686-3696.
[39]Jones S, Holmes F, O'Shaughnessy J, et al. Extended followup and analysis by age of the US oncology adjuvant trial 9735:Docetaxel/ Cyclophosphamide is associated with an OS benefit compared to Doxorubicin /Cyclophosphamide and is welltolerated in women 65 or older. Paper presented at San Antonio Breast Cancer Symposium [C]. San Antonio, Texas, USA,2007.
[40]Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing Doxorubicin plus Cyclophosphamide with Docetaxel plus Cyclophosphamide as adjuvant therapy for operable breast cancer [J]. J Clin Oncol,2006,24(34): 5381-5387.
[41]Nabholtz JM, Pienkowski T, Mackey J, et al. Phase III trial comparing TAC (Docetaxel, Doxorubicin, Cyclophosphamide) with FAC (5-Fluorouracil, Doxorubicin, Cyclophosphamide) in adjuvant treatment of node positive breast cancer patients:Interim analysis of the BCIRG 001 study [J]. Pro Am Soc Clin Oncol,2002,21 (1):36.
[42]Ferguson T, Wilcken N, Vagg R, et al. Taxanes for adjuvant treatment of early breast cancer [DB/CD]. Cochrane Database Syst Rev,2007, (4): CD004421.
[43]PiccartMJ, Burzykowski T, Sledge G, et al. Effects of taxanes alone or in combination with anthracyclines on tumor response, progression-free survival and overall survival in first-line chemotherapy of patients with metastatic breast cancer:An analysis of 4,256 patients randomized in 12 trials [J]. Breast Cancer ResTreat,2005,94:S278.
[44]Blum JL,DierasV,Lo Russo PM, et al. Multicenter, phase Ⅱ study of capecitabine in taxane-p retreated etastatic breast carcinoma patients[J]. Cancer,2001,92: 1759-1768.
[45]Seidman AD. Gemcitabine as single-agent therapy in the management of advanced breast cancer[J]. Oncology,2001,15:11-14.
[46]FeherO,Vodvarka P, Jassem J, et al. First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer:A multicenter, randomized, phase III study[J]. Ann Oncol,2005,16:899-908.
[47]Albain KS, Nag S, Calderillo-Ruiz G, et al. Global phase III study of gemcitabine p lus paclitaxel (GT) vs paclitaxel (T) as frontline therapy formetastatic breast cancer (MBC):First report of overall survival[J]. Proc Am Soc Clin Oncol,2004,23:5.
[48]Zelek L,Barthier S, RiofrioM, et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma[J]. Cancer,2001,92:2267-2272.
[49]He L,Orr GA, Horwitz SB. Novelmolecules that interact with microtubules and have functional activity similar to Taxol[J]. Drug Discov Today,2001,6:1153 1164.
[50]GradisharW, Krasnojon D, Cheporov S, et al. Randomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (p ts)with metastatic breast cancer (MBC) [J]. J Clin Oncol,2007,25(18S):40 s.
[51]Early Breast Cancer Trialists'Collaborative Group (EBCTCG).Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:an overview of the randomised trials[J]. Lancet,2005,365 (9472):1687-1717.
[52]Fisher B,Dignam J,Bryant J,et al. Five versus more t han five years of tamoxifen for lymph node2negative breast cancer:updated findings from the National Surgical Adjuvant Breast and Bowel Project B214 randomized t rial [J]. J N at l Cancer I nst,2001,93 (9):684-690.
[53]MillerWR,Dixon JM. Local endocrine effects of aromatase inhibitorswith the breast[J. J Steroid Biochem Mol Biol,2001,79 (1/5):93-102.
[54]The ATAC Trialists Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer:100-month analysis of the ATAC trial [J]. Lancet Oncol,2008,9(1):45-53.
[55]CoatesAS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer:update of study B IG 1-98 [J]. J Clin Oncol,2007,25 (5):486-492.
[56]王涛,江泽飞.早期乳腺癌术后辅助内分泌治疗的基本原则和新进展[M].肿瘤学杂志,2009,15(9)：783-787.
[57]Vogel C L, Cobleigh M A, Tripathy D, et al. Efficacy and safety of trast uzumab as a single agent in first-line treatment of HER-2-overexpressing metastatic breast cancer. J Clin Oncol,2002,20:719-726.
[58]Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab:updated efficacy and biomarker analyses. Breast Cancer Res Treat,2008,112:533-543.
[59]Burris H 3rd, Yardley D, Jones S, et al. Phase Ⅱ trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. J Clin Oncol,2004,22:1621-1629.
[60]Geyer C E, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER222positive advanced breast cancer. N Engl J Med,2006,355:2733 2743.
[2]Chow LWC,LooWTY. The differential effects of cyclophosphamide, epirubicinand-fluorouracil on apoptotic marker (CPP-32), pro-ap-optotic protein (p21waf-1) and anti-apoptotic protein (bcl-2) in breast cancer cells[J].Breast Cancer Res Treat,2003,80 (3):239-244.
[3]陈孝平,石应康,邱贵兴,主编.外科学[M].北京：人民卫生出版社,2005,439.
[4]常卫华,王留兴等.乳腺癌分子靶向治疗的进展与展望[J].肿瘤基础与临床,2009,22(3)：270-271.
[5]Jacobs JR,Bovasso GB.Early and chronic stress and their relation to breast cancer[J].PsycholMed,2004,30(3):669-678.
[6]朱珍,张凤春.晚期乳腺癌的化疗进展[J].现代肿瘤医学,2009,17(6)：1179-1181.
[7]徐兵河.复发转移乳腺癌的化学治疗[J].中国实用内科杂志,2007,27：24.
[8]Vahdat LT, Tomas E, Li R, et al. Phase III trial of ixabepilone plus capecitabine compared to capecitabine alone in patients with mestastatic breast cancer(MBC) previously treated or resistant to an anthracycline and resistant to taxanes[J].Proc Am Soc Clin Oncol, 2007,25(18s):33s.
[9]Rakha EA,E1 Sayed ME,Green AR Prognostic makers in triple-negative breast cancer[J].Cancer,2007,109:25.
[10]Nielen TO,Hsu FD,Jensen K,et al.Immunolistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma[J].Clin Cancer Res,2004,10:5367-5374.
[11]Banerjee S,Reis Filho JS,Ashley S,et al.Basal-like breast carcinomas:clinical outcome and response to chemotherapy[J] J Clin Pathol,2006,59:729-735.
[12]Dent R,Trudeau M,Pritchard KI,et al.Triple-negative breast cancer:clinical features and patterns of recurrence[J].Clin Cancer Res,2007,13(15):4429-4434.
[13]李庆,范晓磊.中药抗肿瘤的研究进展[J].中国微生态学杂志,2007,19(3)：317-318.
[14]潘启超,胥彬主编.肿瘤药理学与化疗学第二版[M].河南医科大学出版社,郑州,2000;315.
[15]李厚伟,张妍,许超千,等.中药HB对喉癌Hep22细胞的抑制作用及其机制研究[J].哈尔滨医科大学学报,2001,35(4)：261-262.
[16]刘国清,田秉漳,皮执民,等.蜈蚣油性提取液对肝癌细胞增殖的影响[J].中国现代医学杂志,2002,12(4)：55-56.
[17]曾红,张国刚,程巨龙.蜈蚣中抗癌活性成分的提取[J].湖南中医志,2004,20(5)：57-58.
[18]刘细平,钟德玝.蜈蚣提取液对裸鼠移植肝癌抑癌作用及机制的研究.[J].中国普通外科杂志,2010,19(2)：164-168.
[19]Gygi SP, Corthals GL, Zhang Y, et al. Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology[J].Proc Natl Acad Sci U S A, 2000,97(17):9390-9395
[20]Washburn MP, Wolters D, Yates JR, et al. Large-scale analysis of the yeast proteome by multidimensional protein identification technology[J].Nat Biotechnol, 2001,19(3):242-247
[21]Gorg A, Weiss W, and Dunn MJ. Current two-dimensional electrophoresis technology for proteomics[J].Proteomics,2004,4(12):3665-3685
[22]Hancock WS, Wu SL, Shieh P, et al. The challenges of developing a sound proteomics strategy[J].Proteomics,2002,2(4):352-359
[23]Rabilloud T, Blisnick T, Heller M, et al. Analysis of membrane proteins by two-dimensional electrophoresis:comparison of the proteins extracted from normal or Plasmodium falciparum-infected erythrocyte ghosts[J].Electrophoresis,1999, 20(18):3603-3610
[24]Wissing J, Heim S, Flohe L, et al. Enrichment of hydrophobic proteins via Triton X-114 phase partitioning and hydroxyapatite column chromatography for mass spectrometry[J].Electrophoresis,2000,21(13):2589-2593
[25]Pierce WM and Cai J. Applications of mass spectrometry in proteomics[J].Contrib Nephrol,2004,141:40-58
[26]Aebersold R and Mann M. Mass spectrometry-based proteomics[J].Nature, 2003,422(6928):198-207
[27]司秋菊,王鑫国,白霞,等.蜈蚣对动脉粥样硬化家兔血液流变学的影响[J].中国老年学杂志,2004,24(9)：831-833.
[28]焦波,娄红祥,王东兴,等.蜈蚣提取液对小鼠精原细胞的作用[J].山东医科大学学报,1999,37(4)：358.
[29]司徒镇强,吴军正.细胞培养[M].西安：世界图书出版公司,2004,1-37.
[30]赵满仓,魏文清等.MTT法抗肿瘤药敏试验影响因素的探讨[M].临床肿瘤学杂志,2009,14(4)：306-308.
[31]Khar A,Alia AM,Pardhasaradhi BV,et al.Induction of stress recsponse renders human tumor cell lines resistant to curcumin-mediated apoptosis:Role of reactive oxygen intermediates[J].Cell Stress Chaperones,2001;694:368-7.
[32]R.A Weinberg著,詹启敏,刘芝华主译.癌生物学[M].北京科学出版社,2009,716-717.
[33]Henrik Mueller, Matthias U Kassack, Michael Wiese. Comparison of the usefulness of the MTT, ATP, and ealcein assays to predict the potency of cytotoxic agents in various human cancer cell lines[J]. J Biomol Screen,2004,9:506-515.
[34]Tsujimoto Y, Finger LR, Yunis J, et al. Cloning of the chromosome breakpoint of neop lastic B-cell with the t (14; 18) chromosome translocation[J]. Science,1984,226(4678):1097-1099.
[35]Callagy GM, Pharoah PD, Pinder SE. bcl-2 is aprognostic marker in breast cancer independently of the nottingham prognostic index[J]. Clin Cancer Res,2006, 12:2468-2475.
[36]Moreno A, Figueras A, Lloveras B, etal。Apoptosis in ductal carcinoma in situ of the breast [J]1 Breast J,2001,7(4):245-248.
[37]YANG LJ, WANG WL. Establishment of the hepatoma cells which express Bax protein stably and highly and observation of its apoptotic phenomena [J]. Di-si Junyi Daxue Xuebao(J Fourth Mil Med Univ),2002,23(5):455-458.
[38]于冰,孙治君.凋亡相关基因bc122、bax、bad与乳腺癌[J].中国普外基础与临床杂志,2007,14(6)：739-741.
[39]Morizane Y,Honda R,Fukami K,et al.X-linked inhibitor of apoptosis functions as ubiquitin ligase to ward mature caspase-9 and cytosolic Smac/ DIABLO[J] J Biochem (Tokyo),2005,137:125-132.
[40]Yamaguchi H, Paranawit hana SR, Lee MW,et al. Epot hilone B analogue (BMS-247550)-mediated cytotoxicity through induction of Bax conformational change in human breast cancer cells [J].Cancer Res,2002; 62 (2):466.
[41]薛敬礼,李小民,等。人乳腺癌MDA-MB-231细胞裸鼠移植瘤模型的建立及生物学特性研究[J]。Sichuan Journal of Zoology,2006,25 (13): 635-637
[42]孙金中,孙圣荣,等。三种建立小鼠乳腺癌移植模型方法的比较[J]武汉大学学报,2006,27(3)：335-337
[43]Iwanuma Y,Chen F, Egilmez N,et al.Antitumor immune response of human periperal blood lymphocytes coengrafted with tumor into severe combined immmunodeficient mice [J].Cancer Res,1997,57(14):2937-2942.
[44]宋萍,王学美,谢爽,等.鲜壁虎冻干粉抑制H22肿瘤血管生成机理的实验研究[J].中国中西医结合杂志,2006,26(1)：58-62.
[45]孙纪元,朱妙章,王四旺,等.苦马豆素对乳腺癌细胞在体内外生长的抑制作用[J].华西药学杂志,2006,21(3)：221-224.
[46]叶燕丽,周听熙,王莲桂.裸裸鼠的繁殖及在肿瘤学中的应用[J].实验动物科学与管理,2005,22：6-8.
[47]Celinski SA,Fisher WE, Amaya F. etal. Somatostatin receptor gene transfer inhibits established pancreatic cancer xenografts[J]J Surg Res,2003, 115:41-47.
[48]Jean M. Angiogenesis:A boost for tumor starvation[J].Science,2003 301:452-454
[49]Lin A Y,Brophy N, Fisher GA,etal. Phase Ⅱ study of thalidomide in patient s with unresectable hepatocellular carcinoma[J].Cancer,2005,103:119-125
[50]黑振宇,王鲁,金惠铭VEGF与原发性肝癌血管新生关系的研究进展[J].中国微循环,2005,9(4)：292-2
[51]Lenz HJ. Antiangiogenic agents in cancer therapy[J].Oncology(Williston Park),2005,19(4 Suppl 3):17-25
[52]邹奇飞,张峰.肝癌中血管生成素2和血管内皮生长因子的表达及其临床意义[J].江苏医药,2006,32(5)：436-438
[53]Moon WS, Rhyu KH, Kang MJ, et al. Overexpression of VEGF and angiopoietin 2:a key to high vascularit y of hepatocellular carcinoma[J]. Mod Pathol, 2003,16(6):552-557
[54]马铁祥,王志明.血管生成素-2,VEGF和bFGF在人乳腺癌中表达及意义[J].医学临床研究,2006,23(3)：336-339
[55]Pichilue P, Chavez JC, LaManna JC, e t a l. Hypoxic regulation of angiopoietin-2 expression in endothelial cells [J]J Biol Chem,2003,279(13): 12171-12180
[56]Sinha P, Poland J, Kohl S, et al. Study of the development of chemoresistance in melanoma cell lines using proteome analysis. Electrophoresis, 2003,24(14):2386-2404.
[57]Rutherford SL,Lindquist S. HSP90 as a capacitor for morphological evolution[J]. Nature,1998,396 (6709):3362342.
[58]Pandey P,Saleh A,Nakazawa A, et al. Negative regulation of cytoehrome c2mediated oligomerization of Apaf21and activation of proeaspase-9 by heat shock protein 90 [J]. EMBO J,2000,19(16):43104322
[59]Solit DB, Rosen N. Hsp90:a novel target for cancer therapy. Curr Top Med Chem.2006;6(11):1205-1214.
[60]Basso AD, Solit DB, Munster PN, Rosen N. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene.2002;21(8):1159-1166.
[61]Armstrong RN.Structure,catalytic mechanism,and evolution of the glutathione transferases[J].Chem Res Toxicol,1997,10:2
[62]Board PQCoggan M,Chelvanayagam G,et al.Identification, Characterization and crystal structure of the Omega class Glutathione transferases[J]J Biol Chem.2000,275,24798-24806
[61]Meyer DJ,Coles B,Pemble SE,et al.Theta,a new class of glutathione transferases purified from rat and man[J].BiochemJ,1991,274(Pt2):409-414
[64]Wilce MCJ,Parker MW.Structure and function of glutathione S-transferases[J].Biochim Biophys Acta,1994,1205,1-18
[65]Coggan M,Whitbread L,Whitington A et al.Structure and organization of the human Theta-class glutathione S-transferase and D-dopachrome tautomerase gene complex[J].Biochem J,1998,334,617-623
[66]Hayes J D,Pulford DJ.The glutathione S-transferases upergene family:regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance[J].Crit Rev Biochem Mot Biol,1995, 30(6):445-600
[67]Nooter K,de la Riviere GB,Klijn J,et al.Multidrug resistance protein in recurrent breast cancer[J].Lancet,1997,349(9069):1885-1886
[68]Kinloeh A, Tamer V, Wait R, et al. Identification of eitmllinated alpha-
enolase as a candidate autoantigen in rheumatoid arthritis[J]. Arthritis Res Ther.2005,7(6):R1421—1429
[69]Ran G, Adamus G Cellular targets of anti-alpha-enolase autoanti-bodies of patients with autoimmune retinopaifiy[J]. JAutalmmun,2004,23(2):161—167.
[70]Nahm D H. Lee K H, Shim JY Identification of alpha-enolase as an autoanfign asstmiated with sever asthma[J]. J Allergy ClinIhmunol,2006,118(2): 376-381
[71]Ghosh A K, Steele R. Ray R B C-mye promoter-binding pmtein 1 (MBP-1) regulates prestate cancer eall growth hy inhibiting MAPK pathway[J]J Bial Chem,2005,280(14):14325—14330
[72]EjesharK. Krtma C, Caren H, et al.Introduction of in vitro transcribed EN01 mRNA into neuroblastama ceUs inducez cell death [J]BMC Cancer.2005, 5(12。):161—174
[73]Takashima M, KuramJtsu Y, Yokoyama Y. at al Overexpresaion Of alpha enolase in hepatitis C virus-related hepatocellular carcinoma:association with tumor progression as determined by protaomie analysis[J], Proteomics.2005,5(6): 1686—1692.
[74]Chang G C, Liu K J, Hsieh C L, et al Identification of alpha enolase as an autoantigen in lung cancer:its overexpression is assoeiatedwith clinical outcomes[J]. Clin CancerRes,2006,12(19):5746-5754
[75]DiMauro, S.; Miranda, A. F.; Sakoda, S.; Schon, E. A.; Servidei, S.; Shanske, S.; Zeviani, M.:Metabolic myopathies. Am. J. Med. Genet.25:635-651,1986.
[76]Pretsch, W.; Favor, J.:A precise localization of a mouse gene encoding increased phosphoglycerate mutase activity (Pgamlel) on chromosome 19. Mammalian Genome 7:619 only,1996.
[77]Sultana R, Perluigi M, Newman SF Redox proteomic analysis of carbonylated brain proteins in mild cognitive impairment and early Alzheimer's disease.Antioxid Redox Signal.2010 Mar; 12(3):327-36.
[78]Huang LJ, Chen SX, Huang Y.-Proteomics-based identification of secreted protein dihydrodiol dehydrogenase as a novel serum markers of non-small cell lung cancer.Lung Cancer.2006 Oct;54(1):87-94.
[79]Luo Y, Li Y, Lin C:Comparative proteome analysis of splenic lymphocytes in senescence-accelerated mice.Gerontology.2009;55(5):559-69.
[80]Gao YL, Liu P, Sun HL:Proteomic analysis of rat astrocytes and C6 glioma cells] Zhonghua Yi Xue Za Zhi.2007 Dec 25;87(48):3421-4.
[81]Zhang YQ, Li W, Wang GJ:Effect of low dose radiation on human bone marrow mesenchymal stem cells by using proteomic analysis]Zhongguo Shi Yan Xue Ye Xue Za Zhi.2008 Feb;16(1):151-5.
[82]. Turhani D, Krapfenbauer K, Thurnher D:Identification of differentially expressed, tumor-associated proteins in oral squamous cell carcinoma by proteomic analysis.Electrophoresis.2006 Apr;27(7):1417-23.
[83]Lu F, Xia Q, Ma Y:Serum proteomic-based analysis for the identification of a potential serological marker for autoimmune hepatitis.Biochem Biophys Res Commun.2008 Mar 7;367(2):284-90. Epub 2007 Dec 26.
[84]Zephir H, Almeras L, El Behi M:Diversified serum IgG response involving non-myelin CNS proteins during experimental autoimmune encephalomyelitis. J Neuroimmunol.2006 Oct; 179(1-2):53-64.
[85]Michael, D.S,Elmar, N:Immunopharmacology2000,47,163.
[86]Pimkin M, Markham GD.:Inosine 5'-monophosphate dehydrogenase.Adv Enzymol Relat Areas Mol Biol.2009;76:1-53. Review.
[87]Nair V, Shu Q:Inosine monophosphate dehydrogenase as a probe in antiviral drug discovery.Antivir Chem Chemother.2007;18(5):245-58. Review.
[88]Moosavi MA, Yazdanparast R:Distinct MAPK signaling pathways, p21 up-regulation and caspase-mediated p21 cleavage establishes the fate of U937 cells exposed to 3-hydrogenkwadaphnin:differentiation versus apoptosis.Toxicol Appl Pharmacol.2008 Jul 1;230(1):86-96.
[89]Chen L, Pankiewicz KW:Recent development of IMP dehydrogenase inhibitors for the treatment of cancer.Curr Opin Drug Discov Devel.2007 Jul;10(4):403-12. Review.
[90]Kagaya H, Miura M, Saito M:Correlation of IMPDH1 Gene Polymorphisms with Subclinical Acute Rejection and Mycophenolic Acid Exposure Parameters on Day 28 after Renal Transplantation.Basic Clin Pharmacol Toxicol. 2010 Feb 2.
[91]Nakanishi T, Morokata T, Kubo K:Effect of the inosine 5'-monophosphate dehydrogenase inhibitor BMS-566419 on rat cardiac allograft rejection.Int Immunopharmacol.2010 Jan;10(1):91-7. Epub 2009 Oct 18.
[92]Gareth D,Bing ZHANGMetabolic Syndrome X Gene Expression and Protential Treating Using Herbal Medicine[M].Annual Report 2002-2003,Human Nutrition Unit,Sydney University
[93]Brodie AE,Reed DJ.Reversible oxidation of glyceraldehyde-3-dehydrogenase thiols in human lung carcinoma cell by hydrogen peroxidase[J]. Biochem Biophs Res Commun,1987,148:120
[94]Tajima H,Tsuchiya K,Yamada M,et al.Over-expression of GAPDH induces apoptosis in COS-7 cells transfected with colned GAPDH cDNAs [J].Neuroreport, 1999,10(10):2029-2033
[95]Sheline CT,Choi DW,Neuronal death in cultured murine cortical cells in induced by inhibition of GAPDH and triosephosphate isomerase[J].Neurobiol Dis,1998,5(1):45-54
[96]Shashidharan P,Chalmers Redmen RM,Carlile GW,et al.Nuclear translocation of GAPDH-GFP fusion protein during apoptosis[J].Neuroreport,1999,10 (5):1149-1153
[97]Ishitani R,Tanaka M,Sunaga K,et al.Nuclear localization of over-expressed glyceral dehydes-3-phosphatedehydrogenase in cultured cerebellar neurons undergoing apoptosis [J].Mol Pharmacol,1998,53(4):701-707
[98]Ikeguchi M,Hirooka Y.Quantiative analysis of apoptasis-related gene expression in epatocellular carcinoma[J].Cancer,2002,95(9):1938-1945
[99]Sirover MA.New insight into an old protein:the functional diversity of ammalian leraldehyde 3-phosphate dehyrogeenase[J].Biochim Biophys Acta,1999, 1432(2):159-184
[100]Kawamoto RM,Caswell AH..Autophosphorylation of glyceraldehydes-phosphate dehydrogenase and phosphorylation of protein from skeletal muscle microsomes[J].Biochemistry,1986,25:656-661
[101]Crespo E,Macias M,Pozo D,et al.Melatonin inhibits expression of the inducible NO synthase Ⅱ in liver and lung and prevents endotoxemia in lipopolysaccharide-induced multiple organ dysfunction syndrome in rats [J].FASEB J,1999,13(12):1537-1546
[102]Beckett GJ,Hates PC,Hussey AT,et al.Plasma glutation Stranferases measurements in patients with alcoholic cirrhosis[J].Clin Chem Acta,1987,169:85
[103]Sanchez A,Alvarez AM,Pagan R,et al.Fibronectin regulates morphology,cell organization and gene expression of rat fetal hepatocytes in primary culture[J].J Hepatol,2000;32(2):242-250
[104]Jung R, Kruger W, Hosch S, et al.Specificity of reverse transcriptase polymerase chain reaction assays designed for the detection of circulating cancer cells is influenced by cytokines in vivo and in vitro [J].Br J Cancer,1998,78 (9): 1194-1198
[105]5Ball BL,Faouzi S,Boussraie L,et al.Extracellular matrix composition and integrin expression in early hepatocarcinogenesis in human cirrhotic liver[J]J Pathol,1997,181:330-337
[106]傅勇,苏勤,刘彦仿,等.层粘连蛋白诱导体外生长的乳腺癌细胞表达细胞角蛋白19[J].肝脏,2002,7(3)：162-164
[107]Yui S, Nakatani Y, Mikami M.Calprotectin (S100A8/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis-inducing activity.Biol Pharm Bull.2003 Jun;26(6):753-60. Review.
[108]Perera C, McNeil HP, Geczy CL.S100 Calgranulins in inflammatory arthritis.Immunol Cell Biol.2010 Jan;88(1):41-9. Epub 2009 Nov 24. Review.
[109]Halayko AJ, Ghavami S.S100A8/A9:a mediator of severe asthma pathogenesis and morbidity?Can J PhysiolPharmacol.2009Oct;87(10):743-55. Review.
[110]Sroussi HY, Lu Y, Zhang QL.S100A8 and S100A9 inhibit neutrophil oxidative metabolism in-vitro:Involvement of adenosine metabolites. Free Radic Res.2010 Apr;44(4):389-96.
[111]Zhu H, Zeng S, Zeng L. Significance and expression of S100A9 and NMP238 in cervical carcinoma tissues with different concurrent chemoradiotherapy sensitivities.]Zhong Nan Da Xue Xue Bao Yi Xue Ban.2010 Jan;35(1):45-51. Chinese.
[112]Ju W, Yoo BC, Kim IJ.Identification of genes with differential expression in chemoresistant epithelial ovarian cancer using high-density oligonucleotide microarrays.Oncol Res.2009;18(2-3):47-56.
[113]Qin F, Song Y, Li Z.S100A8/A9 Induces Apoptosis and Inhibits Metastasis of CasKi Human Cervical Cancer Cells.Pathol Oncol Res.2009 Dec 3.
[114]Mehul B, Bernard D, Brouard M. Hege Influence of calcium on the proteolytic degradation of the calmodulin-like skin protein (calmodulin-like protein 5) in psoriatic epidermis.Exp Dermatol.2006 Jun;15(6):469-77.
[115]Mehul B, Bernard D, Schmidt R.Calmodulin-like skin protein:a new marker of keratinocyte differentiation.J Invest Dermatol.2001 Jun;116(6):905-9.
[116]Saussez S, Cucu DR, Decaestecker C,et al.Galectin 7(p53-Induced Gene 1):A New Prognostic Predictor of Recurrence and Survival in Stage IV Hypopharyngeal Cancer[J]. Annals of Surgical Oncology,2006,13(7):999-1009
[117]I Saussez S, Decaestecker C, Lorfevre F, ncreased expression and altered intracellular distribution of adhesion/growth-regulatory lectins galectins-1 and-7 during tumour progression in hypopharyngeal and Iaryngeal squamous cell carcinomas.Histopathology.2008 Mar;52(4):483-93.
[118]Demers M, Couillard J, Giglia-Mari G, Increased galectin-7 gene expression in lymphoma cells is under the control of DNA methylation.Biochem Biophys Res Commun.2009 Sep 25;387(3):425-9.
[119]Klima J, Lacina L, Dvorankova B,Differential regulation of galectin expression/reactivity during wound healing in porcine skin and in cultures of epidermal cells with functional impact on migration.Physiol Res.2009;58(6):873-84.
[120]Cada Z, Chovanec M, Smetana K, Galectin-7:will the lectin's activity establish clinical correlations in head and neck squamous cell and basal cell carcinomas? Histol Histopathol.2009 Jan;24(1):41-8.
[121]Than TH, Swethadri GK, Wong J,Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators.Singapore Med J.2008 Apr;49(4):333-8.
[122]Ghavami S, Chitayat S, Hashemi M,S100A8/A9:a Janus-faced molecule in cancer therapy and tumorgenesis.Eur J Pharmacol.2009 Dec 25;625(1-3):73-83.
[123]Ehrchen JM, Sunderkotter C, Foell D, The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer.J Leukoc Biol.2009 Sep;86(3):557-66. Epub 2009 May 18. Review.
[124]Li HL, Chen DD,Li XH, et al. Changes of NF-kB, p53, bcl-2 and caspase in apoptosis induced by JTE-22 in human gastric adenocarcinoma cell line AGS cells: role of reactive oxygen species [J]. World J Gastroenterol,2002,8:431-435.
[125]Saleh HA, Jin B, Barnwell J,Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules.Diagn Pathol. 2010 Jan 26;5:9.
[126]Saloustros E, Mavroudis D.Cytokeratin 19-positive circulating tumor cells in early breast cancer prognosis.Future Oncol.2010 Feb;6(2):209-19.
[127]Zhang X, Chen SB, Chen JX,CK19 mRNA expression in the bone marrow of patients with esophageal squamous cell carcinoma and its clinical significance.Dis Esophagus.2010 Jan 20.
[128]Dos Santos JN, Oliveira GQ, Gurgel CA,Altered expression of cytokeratins in primary, recurrent and syndrome keratocystic odontogenic tumors.J Mol Histol.2009 Aug;40(4):269-75.
[129]Leffler H,Carlsson S,Hedlund M,et al.Introduction to galectins[J]. lycoconj. J.2004,19:433-440
[130]Liu FT,Rabinovich GA.Galectins as modulators of tumour progression[J].Nat Rev Cancer,2005,5(1):29-41
[131]Saussez S, Kiss R. Galectin-7 Review[J].Cell Mol Life Sci 2006,63:686-97
[132]Cao Z, Wu HK, Bruce A, et al.Detection of differentially expressed genes in healing mouse corneas,using cDNA microarrays.Invest[J].Ophthalmol. Vis.Sci.2002,43:2897-2904
[133]Cao Z, Said N, Amin S,et al.Galectins-3 and -7,but not galectin-l,play a role in reepithelialization of wounds[J].J.Biol.Chem.2002,277:42299-42305
[134]Cao Z, Said N, Wu HK, et al. Galectin-7 as a potential mediator of corneal epithelial cell migration.Arch[J].Ophthalmol.2003,121:82-86
[135]Pr Zhu H, Pei HP, Zeng S,ofiling protein markers associated with the sensitivity to concurrent chemoradiotherapy in human cervical carcinoma. J Proteome Res.2009 Aug;8(8):3969-76.
[1]韩双红.蜈蚣的研究进展[J].天津药学,2002,14(5)：13-15.
[2]刘峰.蜈蚣的临床应用及毒性研究[J].广西中医药,1999,22(4)：52-53.
[3]杨永华,张水寒,徐琳本,等.僵蚕、蜈蚣提取工艺的研究[J].中国中药杂志,2001,26(9)：599-601.
[4]许鸣镝,柳雪枚.蜈蚣碱性蛋白SSmp-d的分离纯化及其部分理化性质的鉴定[J].生物化学杂志,1997,13(5)：586-591.
[5]曲爱兵,赵维成,梁良,等.蜈蚣组织提取物抗肿瘤活性的初步研究[J].实用肿瘤学杂志,2003,17(1)：29-30.
[6]迟程.墨江蜈蚣和少棘蜈蚣蚣总油脂化学成分比较[J].中草药,1992,23(2)：104.
[7]方红,邓芬,严宜昌,等.黑头蜈蚣的化学成分[J].中药材,1999,22(5)：226-228.
[8]方红,邓芬,严宜昌,等.多棘蜈蚣化学成分的研究[J].中国医学杂志,1997,32(4);202-203.
[9]张保国,张大禄.动物药[M].北京：中国医药科技出版社,2003,875.
[10]肖培根.新编中药志(第四卷)[M].北京：化学工业出版社,2002,330.
[11]周莉莉,黄迎春,任超.蜈蚣醇提取物和水提取物部分药理作用比较[J].时珍国医国药,2008,19(11)：2697-8.
[12]迟程,罗天浩.蜈蚣毒性与用量的探讨[J].中国中药杂志,1995,15(6)：90-91.
[13]刘峰.蜈蚣的临床应用及其毒性研究[J].广西中医药,1999,22(4)：52-53.
[14]宋建徽,孟祥琴,王永利.蜈蚣提取液的中枢抑制作用及急性毒性[J].河北中医学院学报,1995,16(2)：91-92.
[15]韩双红.蜈蚣的研究进展[J].天津药学2002,14(5)：13-15.
[16]迟程,舒晔,迟萍.墨江蜈蚣和少棘蜈蚣抗惊厥药效学实验研究[J].云南中医学院学报,1992,15(1)：23-24.
[17]陈红琳,李小莉,甘明.墨江蜈蚣的药理作用[J].湖北中医杂志,2003,25(1)：501.
[18]司秋菊,王鑫国,白霞,等.蜈蚣对动脉粥样硬化家兔血液流变学的影响[J].中国老年学杂志,2004,24(9)：831-833.
[19]司秋菊,王亚利,王鑫国,等.蜈蚣有效成分抗心肌缺血作用的研究[J].河北中 医药学报,2001,16(2)：1-3.
[20]司秋菊,王亚利,王鑫国,等.蜈蚣对心肌缺血性损伤小鼠NO及iNOS的影响[J].山东中医杂志,2004,23(8)：492-493.
[21]司秋菊,王鑫国,王亚利,等.蜈蚣对动脉粥样硬化家兔血管内皮细胞功能的影响[J].中药药理与临床,2002,18(6)：28-30.
[22]张艳慧,司秋菊,王鑫国.蜈蚣抗家兔动脉粥样硬化的实验研究[J].中药药理与临床2005；21(1)：26-27.
[23]王亚利,司秋菊,王鑫国,等.蜈蚣对动脉粥样硬化家兔血管平滑肌细胞周期及c-myc基因表达的影响[J].中药药床,2001,17(6)：28-29.
[24]张明泉,王亚利,温瑞书,等.蜈蚣提取液对大鼠心脏血流动力学的作用研究[J].河北中医,2004,26(9)：716-717.
[25]毛小平,陈子君,毛晓建,等.蜈蚣的部分药理研究[J].云南中医学院学报,1999,22(3)：1-4.
[26]曾红,张国刚,程巨龙.蜈蚣中抗癌活性成分的提取[J].湖南中医杂志,2004,20(5)：57-58.
[27]焦波,娄红祥,王东兴,等.蜈蚣提取液对小鼠精原细胞的作用[J].山东医科大学学报,1999,37(4)：358.
[28]李风云,陈浩然,张蓄兰,等.中药制剂抗肿瘤作用的实验研究[J].中医药学报,1999,27(5)：57.
[29]刘德贵,苗艳波,张铁光,等.简述有毒动物药的抗肿瘤作用临床研究[J].吉林中医药,1998,18(6)：61.
[30]李厚伟,张妍,许超千,等.中药HB对喉癌Hep22细胞的抑制作用及其机制研究[J].哈尔滨医科大学学报,2001,35(4)：261-262.
[31]刘国清,田秉漳,皮执民,等.蜈蚣油性提取液对肝癌细胞增殖的影响[J].中国现代医学杂志,2002,12(4)：55-56.
[32]冉泳禄,吴刚,王金焕,等.墨江蜈蚣与少棘蜈蚣的比较研究Ⅱ[J].动物学研究,1996,17(1)：79.
[33]贺巍,叶海英.中药蜈蚣的研究进展[J].中药材,2002,25(2)：152-155.
[34]毛小平,陈子珺,毛晓健,等.蜈蚣的部分药理研究[J].云南中医学院学 报,1999,22(3)：1-3.
[35]李小莉,陈红林,甘民.不同品种蜈蚣的抗炎、镇痛作用[J].中国中药杂志,1996,21(8)：498.
[36]陈红琳,李小莉,甘明.墨江蜈蚣的药理作用[J].湖北中医杂志,2003,25(1)：50-51.
[37]梁洁,黄华营.药用蜈蚣的化学成分及药理活性研究近况[J].广西中医药[J]2005,28(4)：6-7.
[38]张维文,罗健东,张贵平.蜈蚣水提物对动物消化功能的增强作用.[J].中药材,1999,22(10)：518-519.
[39]朱步先.朱良春用药经验[M].上海：上海中医学院出版社,1989 120.
[40]王玉芬,韩双红,曲树明,等.蜈蚣延缓衰老作用的研究[J].中国中药杂志,1994,19(11)：685-687.
[41]任丽虹,郝立君,段国新,等.五倍子、蜈蚣对瘢痕疙瘩成纤维细胞增殖和胶原合成的影响[J].实用美容整形外科杂志,2003,14(6)：324-327.
[42]韩双红,王玉芬,赵泰,等.均肾舒冲剂药理作用的研究[J].中草药,1999,30(4)：282.
[43]方红,邓芬.蜈蚣药材中毒成分组织胺的含量测定[J].中草药,1997,28(8)：472-473.
[44]陶红.牵正蜈蚣散治疗神经系统疾病328例临床体会[J].湖南中医杂志,1990,6(1)：216.
[45]伍玉元.蜈蚣粉致急性肝功能损害2例[J].中国中药杂志,1994,19(1)：50.
[46]赵鹏俊,邹永祥.口服蜈蚣粉致急性肾功能衰竭死亡1例[J].中国中药杂志,1998,23(2)：117.
[47]肖贻纯.蜈蚣、全蝎致神经中毒1例[J].中国中药杂志,1996,21(10)：634.
[48]余圣龙.生蜈蚣致过敏[J].中国中药志,1989,14(5)：56.
[49]陈听.蜈蚣过敏1例[J].四川中医,1997,15(10)：32.
[50]郭志达,吉小莉,宋建贞,等.中药蜈蚣对大鼠心脏毒性作用的初步研究[J].中国临床药理学与治疗学,2000；5(3)：278.
[51]邓芬,方红,王克勤.中药蜈蚣毒溶血活性试验[J].中药材,1997,20(1)：36-37.
[52]虞国茂,沈康.中药蜈蚣对小鼠胚胎发育的影响[J].解剖学杂志,1994,17(1)：56-59.
[53]迟程,罗天浩.蜈蚣毒性与用量的探讨[J].中国中药杂志,1995,15(6)：90-91.
[54]刘峰.蜈蚣的临床应用及其毒性研究[J].广西中医药,1999,22(4)：52-53.
[55]宋建徽,孟祥琴,王永利.蜈蚣提取液的中枢抑制作用及急性毒性[J].河北中医学院学报,1995,16(2)：91-92.
[56]李小莉,陈红琳,甘民.不同品种蜈蚣的抗炎、镇痛作用[J].中国中药杂志,1996,21(8)：498-499.
[57]韩双红.蜈蚣的研究进展[J].天津药学2002,14(5)： 13-15.
[1]Law RenceW,Norton,李芬芳,等.美国乳腺癌治疗现状[J].陕西肿瘤医学,2000,8(2)：123.
[2]Chow LWC,LooWTY. The differential effects of cyclophosphamide,ep irubicinand5-fluorouracil on apoptotic marker (CPP-32), pro-ap-optotic protein (p21waf-1) and anti-apoptotic protein (bcl-2) in breast cancer cells[J]. Breast Cancer Res Treat,2003,80 (3):239-244.
[3]董志伟,乔友林等.中国癌症高发现场报告[J].中国肿瘤,2009,18(1)：4-9.
[4]陈孝平,石应康,邱贵兴,主编.外科学[M].北京：人民卫生出版社,2005.439.
[5]常卫华,王留兴等.乳腺癌分子靶向治疗的进展与展望[J].肿瘤基础与临床,2009,22(3)：270-271.
[6]Jacobs JR,Bovasso GB. Early and chronic stress and their relation to breast cancer[J]. PsycholMed,2004,30 (3):669-678.
[7]朱珍,张凤春.晚期乳腺癌的化疗进展[J].现代肿瘤医学,2009,17(6)：1179-1181.
[8]徐兵河.复发转移乳腺癌的化学治疗[J].中国实用内科杂志,2007,27：24.
[9]商宏恺,童晓文.乳腺癌手术治疗的演变[M].中国实用妇产与产科杂志,2008,24(11)：808-810.
[10]HalstedWS. The results of operations for cancer of breast performed at the Johns Hopkins hospital from June1889 to January1889 [J].Joh Hop Bul,1894,4:294.
[11]Urban JA,Baker HW. Radical mastectomy with en bloc resection of the Intelmammary lymph node chain:a new procedure for primary operable cancer of the breast[J]. Cancer,1952,5 (5):992-1008.
[12]Fisher B, Jeong J H,Anderson S,et al.Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation[J]. N Engl J Med,2002,347 (8):567.
[13]王先明.乳腺癌手术治疗的历史演变与现代进展[J].中国现代手术学杂志,2003,7(6)：467-471.
[14]Smit JJ, SchinkelAH,Oude Elferink RPJ, et al. Homozygous disruption of the murine mdrz pglycop rotein gene leads to a comp lete absence of phospholip id from bile and to liver disease[J]. Cell,1993,75(3):451-462.
[15]Veronesi U, Banfi A, Salvadori B, et al. Breast conservation is the treatment of choice in small breast cancer:long-term results of a randomized trial. Eur J Cancer,1990,26:668-670.
[16]Fisher B, Anderson S, Redmond CK, et al. Reanalysis and result s after 12 years of follow-up in a randomized clinical trial comparing total mastectomy wit h lumpectomy wit h orwit hout irradiation in the treatment of breast cancer [J]. NEngl J Med,1995; 333 (22):1456-1461
[17]National Surgical Adjuvant Breast and Bowel Project (NSABP).Progress Report [R]. July 1998:31-39.
[18]Sarrazin D, Arriagada R, Contesso G, et al. Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer. Radiother Oncol,1989,14:177-184.
[19]Cutuli B,Nir CCS,Lafontan BD,et al.Brast-conserving therapy for ductal carcinoma in situ of the Breast:the French Cancer centers experience[J].Int J Radia Oncol Biol Phys,2002,53:868-879.
[20]Hiotic K,Ye W, Sposto R,et al.Predictors of breast conservation the rapy size is not all thatmatters[J]. Cancer,2005,103(5):892-899.
[21]叶再元,蒋劲松.乳腺癌外科治疗新进展[J].现代实用医学,2005,17(12)：730-732.
[22]郭小毛,梅欣等.局部晚期乳腺癌的治疗进展[J].中国癌症杂志,2006,16(6)：409-416.
[23]Reed J, Rosman M, Verbanac KM, et al. Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer:10-year analysis of patients enrolled in the prospective East Carolina University/Anne Arundel Medical Center Sentinel Node Multicenter Study[J]. J Am Coll Surg,2009,208(3):333-340.
[24]Sato K, Shigenaga R. Sentinel lymph node biopsy for breast cancer[J]. J Surg Oncol,2007,96:322-329.
[25]邵志敏,沈镇宙.21世纪乳腺癌治疗的展望[M].中国癌症杂志,2005,15(5)：405-407
[26]Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemot-herapy. Danish Breast Cancer Cooperative Group 82b Trial [J]. N Engl J Med,
1997; 337 (14):949-955.
[27]Whelan TJ,J ulian J,Wright J,et al.Does locoregional radiation therapy improve survival in breast cancer?A meta-analysis A meta-analysis [J] J Clin Oncol,2000; 18 (6):1220-1229.
[28]Recht A,Edge SB,Solin LJ,et al.Postmastectomy radiotherapy:clinical practice guidelines of the American Society of Clinical Oncology [J]. J Clin Oncol,2001;19(5):1539-1569.
[29]于世英.放疗在乳腺癌治疗中作用[J].临床外科杂志,2000,8(5)：261.
[30]薛军,程晶等.不同放化疗模式治疗局部晚期乳腺癌的疗效分析[J].肿瘤防治研究,2009,36(10)：876-878.
[31]余子豪,乳腺癌.[M]//殷蔚伯,谷铣之.肿瘤放射治疗学.3版.北京：中国协和医科大学出版社,2002：1077-1078.
[32]Early Breat Cancer TrialistsI Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:An overview of the randomised trials [J]. Lancet,2005, 365 (9742):1687-1717.
[33]Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide methotrexate, and fluorouracil in node -positive breast cancer the results of 20 years of follow-up [J]. N Engl J Med,1995,332 (14):901.
[34]Bonadonna G, Moliterni A, Zambetti M, et al.30 years follow up of randomized studies of adjuvant CMF in operable breast cancer, cohort study[J]. BMJ 2005,330:217.
[35]Early Breast Cancer Trialists's Collaborative Group. Multi-agent chemotherapy for early breast cancer DB/CD]. Cochrane Database Syst Rev,2002, (1):CD000487.
[36]Poole CJ, Earl HM, Hiller L, et al. Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as adjuvant therapy for early breast cancer [J].N Engl J Med,2006,355 (18):1851-1862.
[37]Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer[J].J Clin Oncol,2003,21 (6):976-983.
[38]Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after Doxorubicin plus Cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer:Results from NSABP B-28 [J]. J Clin Oncol,2005,23 (16): 3686-3696.
[39]Jones S, Holmes F, O'Shaughnessy J, et al. Extended followup and analysis by age of the US oncology adjuvant trial 9735:Docetaxel/ Cyclophosphamide is associated with an OS benefit compared to Doxorubicin /Cyclophosphamide and is welltolerated in women 65 or older. Paper presented at San Antonio Breast Cancer Symposium [C]. San Antonio, Texas, USA,2007.
[40]Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing Doxorubicin plus Cyclophosphamide with Docetaxel plus Cyclophosphamide as adjuvant therapy for operable breast cancer [J]. J Clin Oncol,2006,24(34): 5381-5387.
[41]Nabholtz JM, Pienkowski T, Mackey J, et al. Phase III trial comparing TAC (Docetaxel, Doxorubicin, Cyclophosphamide) with FAC (5-Fluorouracil, Doxorubicin, Cyclophosphamide) in adjuvant treatment of node positive breast cancer patients:Interim analysis of the BCIRG 001 study [J]. Pro Am Soc Clin Oncol,2002,21 (1):36.
[42]Ferguson T, Wilcken N, Vagg R, et al. Taxanes for adjuvant treatment of early breast cancer [DB/CD]. Cochrane Database Syst Rev,2007, (4): CD004421.
[43]PiccartMJ, Burzykowski T, Sledge G, et al. Effects of taxanes alone or in combination with anthracyclines on tumor response, progression-free survival and overall survival in first-line chemotherapy of patients with metastatic breast cancer:An analysis of 4,256 patients randomized in 12 trials [J]. Breast Cancer ResTreat,2005,94:S278.
[44]Blum JL,DierasV,Lo Russo PM, et al. Multicenter, phase Ⅱ study of capecitabine in taxane-p retreated etastatic breast carcinoma patients[J]. Cancer,2001,92: 1759-1768.
[45]Seidman AD. Gemcitabine as single-agent therapy in the management of advanced breast cancer[J]. Oncology,2001,15:11-14.
[46]FeherO,Vodvarka P, Jassem J, et al. First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer:A multicenter, randomized, phase III study[J]. Ann Oncol,2005,16:899-908.
[47]Albain KS, Nag S, Calderillo-Ruiz G, et al. Global phase III study of gemcitabine p lus paclitaxel (GT) vs paclitaxel (T) as frontline therapy formetastatic breast cancer (MBC):First report of overall survival[J]. Proc Am Soc Clin Oncol,2004,23:5.
[48]Zelek L,Barthier S, RiofrioM, et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma[J]. Cancer,2001,92:2267-2272.
[49]He L,Orr GA, Horwitz SB. Novelmolecules that interact with microtubules and have functional activity similar to Taxol[J]. Drug Discov Today,2001,6:1153 1164.
[50]GradisharW, Krasnojon D, Cheporov S, et al. Randomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (p ts)with metastatic breast cancer (MBC) [J]. J Clin Oncol,2007,25(18S):40 s.
[51]Early Breast Cancer Trialists'Collaborative Group (EBCTCG).Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:an overview of the randomised trials[J]. Lancet,2005,365 (9472):1687-1717.
[52]Fisher B,Dignam J,Bryant J,et al. Five versus more t han five years of tamoxifen for lymph node2negative breast cancer:updated findings from the National Surgical Adjuvant Breast and Bowel Project B214 randomized t rial [J]. J N at l Cancer I nst,2001,93 (9):684-690.
[53]MillerWR,Dixon JM. Local endocrine effects of aromatase inhibitorswith the breast[J. J Steroid Biochem Mol Biol,2001,79 (1/5):93-102.
[54]The ATAC Trialists Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer:100-month analysis of the ATAC trial [J]. Lancet Oncol,2008,9(1):45-53.
[55]CoatesAS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer:update of study B IG 1-98 [J]. J Clin Oncol,2007,25 (5):486-492.
[56]王涛,江泽飞.早期乳腺癌术后辅助内分泌治疗的基本原则和新进展[M].肿瘤学杂志,2009,15(9)：783-787.
[57]Vogel C L, Cobleigh M A, Tripathy D, et al. Efficacy and safety of trast uzumab as a single agent in first-line treatment of HER-2-overexpressing metastatic breast cancer. J Clin Oncol,2002,20:719-726.
[58]Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab:updated efficacy and biomarker analyses. Breast Cancer Res Treat,2008,112:533-543.
[59]Burris H 3rd, Yardley D, Jones S, et al. Phase Ⅱ trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. J Clin Oncol,2004,22:1621-1629.
[60]Geyer C E, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER222positive advanced breast cancer. N Engl J Med,2006,355:2733 2743.